Différentes stratégies en Indonésie pour combattre Plasmodium falciparum by Ramadani, Arba Pramundita
HAL Id: tel-02361858
https://tel.archives-ouvertes.fr/tel-02361858
Submitted on 13 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Various antimalarial strategies in Indonesia to fight
Plasmodium falciparum
Arba Pramundita Ramadani
To cite this version:
Arba Pramundita Ramadani. Various antimalarial strategies in Indonesia to fight Plasmodium falci-
parum. Human health and pathology. Université Paul Sabatier - Toulouse III, 2017. English. ￿NNT :
2017TOU30182￿. ￿tel-02361858￿
 
THESIS 
 
In order to obtain 
 
DOCTORATE OF UNIVERSITÉ DE TOULOUSE 
 
Issued by Université Toulouse III – Paul Sabatier  
Speciality: Pharmacology 
 
Presented by: 
Arba Pramundita Ramadani 
 
Title:  
Various Antimalarial Strategies in Indonesia to Fight Plasmodium falciparum  
 
 
JURY 
Françoise BENOIT-VICAL  Research Director INSERM, Toulouse Thesis Promotor 
Mustofa University Professor, Indonesia Thesis Co-
Promotor 
Alexis VALENTIN University Professor – Hospital Practitioner, 
Toulouse 
Examiner 
Mahardika Agus Wijayanti Research Director Faculty of Medicine, UGM, 
Indonesia 
Examiner 
Supargiyono University Professor, Indonesia Reviewer 
Iwan Dwiprahasto University Professor, Indonesia Reviewer 
Sofia Mubarika Harjana University Professor, Indonesia Reviewer 
 
 
 
Doctoral Program Biologie – Santé – Biotechnologie 
Research Unit LCC-CNRS, UPR8241 Toulouse, France 
Thesis Promotors Françoise BENOIT-VICAL and Mustofa 
 
 
 
 
  
 
 
  
  
iii 
 
ACKNOWLEDGMENT 
Owing to Allah the Almighty mercy and blessings, I could finally complete this dissertation 
entitled "Various antimalarial strategies to fight Plasmodium falciparum in Indonesia". This 
means my long full-of-romance journey at Université Toulouse III - Paul Sabatier and Gadjah 
Mada University is over. Having completed this study, I hope to get the ease and ways to learn 
from this journey, so I can dedicate the rest of my life to the benefit of my family, institution, 
and community through the will of Allah the Almighty. 
First of all, I would like to thank Dr. Azzedine BOUSSEKSOU for accepting me into the 
research group in LCC-CNRS and Prof. Nicolas FABRE for allowing me to conduct the 
research in Pharmadev. 
I am deeply indebted to Dr. Françoise Benoit-VICAL as my supervisor who has kept on 
guiding me as her “student daughter” from the very beginning until the end of my writing with 
her patience and wisdom. I learn a lot from her scientific ways of thinking, the exchanges of 
ideas and issues, immense knowledge and lot other things.  
Grateful acknowledgement is also made to Prof. Dr. Mustofa, M.Kes. Apt, my Co-Supervisor 
who provided me an opportunity and continuous support during my study and related research. 
His patience and guidance helped me in all the time of research and writing this dissertation. 
His wisdom teaches me a lesson never being taught in class or written in a book.  
A profound gratitude to the members of my dissertation defence committee: Prof. Alexis 
VALENTIN and Dr. dr. Mahardika Agus Wijayanti, DTM&H, M.Kes. as the examiner; also 
Prof. Iwan Dwiprahasto, Prof. Supargiyono and Prof. Sofia Mubarika Harjana as the reviewer 
of my dissertation. 
This dissertation has gone through several steps, including research experiment, data analysis, 
writing, and editing. I owe a favour to my lab mates who always cheered up my days in the 
laboratory. Sokhna, who helped me in days of my adaptation to new environment, my mentor 
to talk in French and who treated me as her little sister. This also goes to Hugo and Petty for 
the adorable assistance, Lucie for the warm friendship, and Quan for his kindness. I would also 
like to say thanks to Haouaria and Laila for their help, Eric for heartfelt welcome. My high 
appreciation goes to Jean-Michel who always supported me with ideas, advice and lots of 
journals to read. I am also grateful to other group V members, Dr. Catherine HEMMERT and 
Prof. Heinz GORNITZKA for the encouragement. Special acknowledgment goes to my 
colleagues in Universitas Islam Indonesia (UII), particularly to mas Anshory who helped me 
in collecting the plants and extraction process, mbak Asih who willingly helped with my 
administrative inquiry in UPS, and Ms. Heni who has done me a favour to edit and proofread 
the language in this dissertation.   
I would like to say thank you also to the many members of PPI (Persatuan Pelajar Indonesia) 
Toulouse who always helped and kept me company in my social life there. 
My deepest gratitude goes to Kupang research team, Bu Eti, Mbak Priska and others who made 
the study possible to begin. I would also like to thank BPOM Kupang for allowing me to use 
the microbiology laboratory for my research and the Department of Health of Kupang for the 
research permission. 
  
iv 
 
Last but not least, I do hope this dissertation can be one of the ways to show my respect and 
gratitude to my honourable parents, in-laws, and siblings. Finally, I dedicate this dissertation 
to my soul mate as well as friend in sailing over this beautiful, amazing life, my beloved 
husband, Ruby. May we get a lot of blessings from this struggle. 
Whispering my prayers, I wish the aforementioned people and those unstated here, who have 
helped me in this study and gone through the process with me, receive the blessings and glory 
from Allah here and after. Amen. 
 
Yogyakarta, July 2017 
 
Arba Pramundita Ramadani 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
v 
 
 
 
 
 
 
 
For indeed, with hardship (will be) ease. Indeed, with 
hardship (will be) ease. 
[QS.94 :5-6] 
 
A chaque problème il y une solution. S’il n’y a pas de 
solution, c’est qu’il n’y avant pas de problème.  
[FBV] 
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Various antimalarial strategies in Indonesia to fight Plasmodium falciparum  
 
ABSTRACT 
Malaria remains a global public health problem and worsening with the resistance of 
Plasmodium falciparum to Artemisinin-based Combination Therapies (ACTs), the latest and 
most effective antimalarial drugs. My project aimed to provide insight into malaria elimination 
in Indonesia. The first part was to look for new antimalarial drugs based on Indonesian 
ethnobotanical data. Among 25 crude extracts realized on Indonesian traditional medicinal 
plants, seven showed a good antimalarial activity (IC50 < 5µg/mL) and some of them were also 
active against Babesia divergens and Leishmania infantum. The second part of the study 
focused on chemosynthetic organometallic compounds. The structure-activity relationships 
study on organometallic gold(I)-NHC complexes led to a very active compound on P. 
falciparum with an IC50 of 320nM. The third part of this work was dedicated to the study of P. 
falciparum resistance to artemisinin and its derivatives. The correlation between PfK13 
polymorphism and artemisinin resistance has been clearly established thanks to reverse genetic 
with resistant and sensitive laboratory strains and clinical isolates from Cambodia. This 
resistance was evidenced in vitro throughout a parasite survival assay called RSA(0-3h). By the 
same genotypic and phenotypic methods, mapping of PfK13 polymorphism distribution in 
Indonesia was performed in Kupang on P. falciparum malaria patients. However, at the time 
of P. falciparum blood samples collection, prevalence showed a dramatic decrease hindering 
the continuation of the clinical study. Facing to the very small number of eligible patients with 
a P. falciparum malaria, no conclusive results has been obtained. In conclusion, medicinal 
plants and synthetic compounds are potentially interesting as chemical starting point for new 
antimalarial drugs. Concerning artemisinin resistance, any treatment failure or delayed cure 
with ACTs has yet to be reported in Indonesia. However, because Indonesia is relatively close 
to the Southeast Asian areas of resistance, the possible occurrence of such cases in Indonesia 
must be anticipated by determining the variations of P. falciparum malaria chemo-sensitivity 
and by following PfK13 polymorphism, responsible for artemisinin resistance.  
 
Keywords : malaria, Plasmodium falciparum, traditional medicine, PfK13, artemisinin, 
resistance 
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Différentes stratégies en Indonésie pour combattre Plasmodium falciparum  
 
RESUME 
Le paludisme demeure un problème de santé publique mondial qui risque de s'aggraver avec la 
résistance de Plasmodium falciparum aux thérapies combinées à base d'artémisinine (ACT), 
médicaments antipaludiques les plus récents et les plus efficaces. Mon travail avait pour but de 
proposer différents axes d'élimination du paludisme en Indonésie.  
Une première partie a consisté à rechercher de nouveaux médicaments antipaludiques à partir 
de données ethnobotaniques indonésiennes. Parmi les 25 extraits bruts réalisés à partir de 
plantes médicinales indonésiennes utilisées traditionnellement dans le traitement du paludisme, 
sept ont montré une activité antipaludique intéressante (CI50 <5 μg/mL) et certains d'entre eux 
se sont révélés également actifs sur 2 autres pathogènes Babesia divergens et Leishmania 
infantum. La deuxième partie de ce travail était axée sur les composés organométalliques 
synthétiques. Les études de relations structure-activité de ces complexes organométalliques 
d'or (I) -NHC ont permis de sélectionner un composé actif sur P. falciparum avec une CI50 de 
320nM. La troisième partie du travail a été consacrée à l'étude de la résistance de P. falciparum 
à l'artémisinine et à ses dérivés. La corrélation entre le polymorphisme de PfK13 et la résistance 
à l'artémisinine a été clairement établie grâce à des études de génétique inverse avec des 
souches de laboratoire résistantes et sensibles et des isolats cliniques Cambodgiens. Cette 
résistance a été mise en évidence in vitro par un test de survie parasitaire appelé RSA(0-3h). Par 
les mêmes méthodes génétique et phénotypique, la cartographie de la distribution du 
polymorphisme de PfK13 en Indonésie a été réalisée dans la zone de Kupang sur des patients 
infectés par P. falciparum. Cependant au moment de la collecte des échantillons de sang, la 
prévalence de P. falciparum a montré une diminution spectaculaire empêchant la poursuite de 
l’étude clinique. Face au faible nombre de patients admissibles avec un paludisme à P. 
falciparum, aucun résultat concluant n’a pu être obtenu.  
En conclusion, les plantes médicinales indonésiennes et les composés synthétiques sont 
potentiellement intéressants comme point de départ chimique pour de nouveaux médicaments 
antipaludiques. En ce qui concerne la résistance à l'artémisinine, aucun échec thérapeutique ou 
parasitologique après traitement par ACT n’a été signalé, pour le moment, en Indonésie. 
Cependant, les zones de résistance de P. falciparum aux ACT dans le Sud-Est asiatique sont 
relativement proches et nécessitent, en Indonésie, un suivi des variations de la chimiosensibilité 
du paludisme à P. falciparum et du polymorphisme de PfK13, responsable de la résistance à 
l'artémisinine. 
 
Mot de clé : paludisme, Plasmodium falciparum, traditionnel médicine, PfK13, artemisinin, 
résistance 
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INTRODUCTION 
Malaria is a tropical infectious disease, which continues to be one of the largest public 
health problems in developing countries. According to the World Health Organization (WHO), 
there were approximately 212 million cases worldwide in 2015 [1]. Most of them occurred in 
Africa (90%) followed by South East Asia (7%), including Indonesia that shared 9% malaria 
cases of SEA region in 2015 [1]. In Indonesia, based on the latest data collection, there were 
252,027 positive cases reported in 2014 [2]. Although morbidity and mortality statistics are 
routinely under-reported [3], annual parasite incidence (API) is used to determine the morbidity 
trend and endemicity  area in Indonesia [2]. The latest report from Indonesian Ministry of 
Health (MoH) stated that the national API in 2015 was 0.85 per 1,000 population. However, 
several provinces showed higher API level than national level, such as Papua (31.93), West 
Papua (31.29), East Nusa Tenggara (7.04), Maluku (5.81), North Maluku (2.77), Bengkulu 
(2.03), and Bangka-Belitung Island (1.08) [4]. Almost 60% of malaria cases in Indonesia are 
caused by Plasmodium falciparum followed by Plasmodium vivax (40% approximately) with 
different proportion in each endemic region [5].  
Even though some reports stated minor prevalence in several endemic regions, the 
malaria remains a constant strike each year [6]. Hence, the continuous effort to eliminate 
malaria in Indonesia is imperative and many Indonesian scientists explore ethno-botanical data 
to find efficient medicinal plants allowing the discovery of new antimalarials. However, many 
studies were promptly stopped often due to un-standardized method of assays or sample 
preparations.  Moreover, several promising medicinal plants are endangered due to lacking of 
knowledge on its cultivation process and uncontrolled harvesting. All of them make the process 
of discovering new antimalarials from plants come too far from clinical implementation. 
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Indeed, exploring medicinal plants remains a common way to discover new drugs. In 
endemic areas, medicinal plants are the most affordable treatments [7] and compounds such as 
alkaloids, terpenoids, flavonoids, and others possess antiplasmodial activity [8]. As Indonesia 
has abundant sources of medicinal plants for traditional disease treatments, people excessively 
use them until today. For example, malaria is commonly treated using herbal medicinal 
products, particularly to reduce fever simply by using them as patch, drinking brew preparation 
or decoction. Several plants naturally growing in Indonesia and widely used to treat malaria 
include T. diversifolia, C. barbata, T. crispa, A. flava and P. cauliflora. These plants offer an 
opportunity to discover new antimalarial drugs through assessment their antiplasmodial 
activities in conjunction with cytotoxic assays to determine their selectivity. Their activity 
profile can be extended to some other parasites like Babesia close to Plasmodium or Leshmania 
for which an overlapping in geographic distribution exists with Plasmodium and can be at the 
origin of co-infections in human [9]. 
The identification of new chemical entities (NCEs) can be sourced by chemical 
synthesis [10]. Among synthetic drugs, organometallic compounds, such as gold complexes, 
are particularly interesting due to the intrinsic activity of the metallic moieties able to increase 
the efficacy of organic drugs. As a result, it has been published that cationic lipophilic gold (I)-
NHC complexes were active against chloroquine-resistant P. falciparum strain possibly due to 
the respective positive influence between cationic gold and the presence of nitrogen or sulfur 
atoms in the ligands [11].   
Apart from discovering new drugs, the Indonesian Ministry of Health (MoH) actively 
launched the malaria elimination program. Comprehensively, the program covers surveillance 
and vector control, early diagnosis procedure and fast precise treatments in order to stop 
malaria spreading [12]. Concerning therapies, the Indonesian government follows and adjusts 
its treatment policy to the WHO recommendations. Accordingly, Artemisinin-based 
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Combination Therapies (ACTs) have been implemented as the first line therapy for 
uncomplicated malaria since 2006 especially as many studies revealed the resistance of 
Plasmodium to non-artemisinin therapies in several regions [13] [14]. 
ACTs, a combination of artemisinin or one of its derivatives (artesunate, artemether, or 
dihydroartemisinin) with an antimalarial drug partner belonging to a different chemical class 
[15], are recommended by the WHO [16, 17]. However, although artemisinin is the most potent 
antimalarial drug, several studies reported a decreasing parasite susceptibility to artemisinins 
characterized by delayed parasite clearance times, a sign that artemisinin resistance occur [18-
20]. In addition, recent findings figured out that the resistance can be also extended to the 
companion drug of some ACTs, such dihydroartemisinin-piperaquine (DHP) [21], recently 
implemented in Indonesia. 
The mechanism of artemisinin resistance is different from those involved in other 
antimalarial drug resistances. This mechanism is based on an entrance in a quiescence state, 
allowing parasites to survive against high doses of artemisinin at the ring stage. Parasites can 
resume a regular cycle after the removal of drug [22]. This phenomenon is not observable by a 
standard chemo-sensitivity assay, but by ring-stage survival assay (RSA), which evaluates the 
susceptibility of P. falciparum to artemisinin [23] and reflects the ability of parasites to survive 
ART treatment [22]. Further investigations found that mutations of K13 propeller, involved in 
protein ubiquitination, were correlated to artemisinin resistance [24]. In order to discover new 
targets to overcome this artemisinin resistance, it is necessary to clarify the role of K13 
mutations. This is achieved by both insertion and removal of mutated or wild type Pfk13 genes 
on clinical isolates and several P. falciparum laboratory lines [25].  
Interestingly, for the moment, K13 mutations are found to play a role in artemisinin 
resistance only in Asia and have been studied and documented in Cambodia, Thailand, 
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Myanmar, Laos, Vietnam [26, 27], and China [28-32] but are not correlated with any case of 
resistance in Africa [26, 28]. Since Indonesia lies close to regions where artemisinin resistance 
emerges and spreads with a strong correlation with K13 mutations, it is highly likely that the 
phenomenon also occurs in Indonesia. The evaluation of clinical, in vitro and genotypic chemo-
sensitivity to DHP in Kupang, a region of high malaria prevalence, could provide a new outlook 
on antimalarial resistance in Indonesia. 
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CHAPTER I 
LITERATURE REVIEW 
 
1. Malaria  
Physicians have diagnosed and treated fevers for thousands of years. Until Robert 
Koch, Louis Pasteur, and their contemporaries uncovered that “germs” were the cause of most 
febrile illness, fevers were considered as a disease and not the result of the disease. Malaria-
like febrile illnesses (with names like “the ague” or “paludisme”) have been described since 
Hippocrates as periodic fevers were and associated with marshes and swamps [33]. In-depth 
malaria studies were feasible after the discovery of the parasite responsible for the illness by 
Charles Louis Alphonse Laveran in 1880 and the parasite transmission to humans by 
mosquitoes by Ronald Ross in 1897 [34]. Globally, malaria is a disease caused by a parasite of 
the genus Plasmodium, which is transmitted to human and widespread through female 
Anopheles mosquito bites.  
There are five species of human malaria parasite: Plasmodium falciparum, P. vivax, P. 
ovale, P. knowlesi and P. malariae which have different world distributions thought 
overlapping exists. The first symptoms of malaria are nonspecific and similar to influenza 
(chills, headache, nausea, fatigue, muscle pain, and rigors). The onset of the symptoms is 
between 1 to 3 weeks after the infection consecutively to a mosquito bite. Fever may appear 2 
-3 days after initial symptoms and may follow a pattern of every 2 or 3 days for P. vivax, P. 
ovale, and P. malariae infections. With P. falciparum fever can be erratic and may not follow 
specific patterns [35]. 
Plasmodium vivax is mostly found in Middle America, North Africa, and Middle East. 
The other parasites, P. ovale is highly present in Africa and P. malariae is widespread around 
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the world.  P. knowlesi, a Plasmodium species naturally living in macaques, has been positively 
found in human in Borneo [36], particularly in people living in the natural habitat of simian 
hosts [37]. Plasmodium knowlesi widely exists in west of the Wallace Line in Indonesia (which 
runs between Borneo and Sulawesi; as well as between Bali and Lombok) [3]. Plasmodium 
falciparum, the deadliest one, is common in West and East Africa, Haiti, the Dominican 
Republic, part of Amazon (South America), and South East Asia [35] including Indonesia.  
Based on the WHO report, malaria caused 429,000 casualties with 303,000 deaths of 
children under 5 years old in 2015 worldwide [1]. In Indonesia, 80 % malaria cases were found 
in Papua, West Papua, East Nusa Tenggara (NTT), Maluku, North Maluku and Bengkulu [2, 
4]. These provinces are the top-6 provinces with highest malaria rate and have higher level of 
annual parasite incidence than the national level (0.85/10,000 population) [4]. The Indonesian 
Ministry of Health stated that in 2014 there were 58 districts /cities considered as high risk 
areas with 3% population (6,331,381) living there [2]. Furthermore, malaria cases in Indonesia 
are mainly caused by Plasmodium falciparum (60% approximately) and by P. vivax (almost 
40%) [5].  
 
2. The Life Cycle of Plasmodium 
The life cycle of malaria parasite is complex (Fig. 1). Motile sporozoites are transmitted 
directly into the human bloodstream by the bite of infected female mosquitoes of the genus 
Anopheles during its blood meal. Within minutes after the bite, the sporozoites circulate briefly 
in human blood before invading hepatocytes, where for the parasite an asexual life cycle and 
an important proliferation ensue. Between 5 and 15 days after (depending on the species) 
thousands of daughter merozoites are released into the blood stream after the rupture of infected 
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hepatocytes. The merozoites then invade circulating erythrocytes for the clinically important 
intra-erythrocytic cycle of 48-hour asexual replication [38, 39].  
Plasmodium falciparum differs from other human malarial parasites species in that 
infected erythrocytes do not remain in the bloodstream. After a maturation of 24-32 hours 
parasites passing as ring stage at the trophozoite stage, parasitized erythrocytes adhere to 
micro-vessel endothelial cells of various organs (called sequestration). Trophozoites then 
mature into schizonts with an egress of 48 hours after the beginning of the erythrocytic 
infection, of 16-31 daughter merozoites that invade non-infected erythrocytes to perpetuate the 
asexual life cycle. Some parasites inside red blood cells differentiate (in response to stress or 
other cues) into male and female gametocytes. Consecutively to their ingestion by a female 
mosquito during its blood meal, they undergo a sexual development [38, 39] .  
The formation of male and female gametes results in a rapid maturation of the 
gametocytes in the mosquito gut (10-20 min). One female gamete emerges from one female 
gametocyte, and three mitotic division cycles give rise to eight male gametes from a single 
male gametocyte. Fertilization of a female gamete by a male gamete produces a zygote (the 
only diploid stage), which undergoes rapid meiotic division and mitosis leading to numerous 
new haploid sporozoites in an oocyst. Then sporozoites migrate to the salivary gland and await 
introduction into a host during the next blood feeding, thereby ensuring the continuation of the 
parasite life cycle [40, 41].  
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Figure 1. The life cycle of P. falciparum 
 [42] 
 
3. Antimalarial Drug 
Malaria was among the first diseases to be treated by a pure chemical compound – 
quinine - isolated from the cinchona bark in 1820. Historically, two herbal treatments for 
malaria fevers, cinchona bark and qinghao, were used to effectively treat malaria for hundreds 
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of years. Today, both derivatives of quinine and artemisinin (from qinghao) remain major in 
the control of malaria [33]. 
 
 
Figure 2. Mode of action of antimalarial drug at the erythrocytic 
[43-45] 
Antimalarials belong to different chemical series with different modes of action (Fig. 
2). They target the red blood stage and the merozoite production, some of the gametocytes, and 
for others also the hepatic stages. In the food vacuole, the polymerization of hemozoin 
corresponding to the detoxification process of wastes due to haemoglobin digestion is affected 
by quinolines [43] and artemisinins. Artemisinin and its derivatives are also responsible for 
alkylation of proteins and heme leading to oxidation damages [46]. At the mitochondrion level, 
atovaquone, targeting the cytochrome bc1 complex, inhibits the parasitic electron transport 
chain and respectively the dihydroorotate dehydrogenase (DHODH) linked to the respiratory 
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chain and implicated in the pyrimidine nucleotides biosynthesis. Antifolates like proguanil and 
pyrimethamine inhibit the folic acid action involved in the DNA and RNA synthesis by 
blocking the dihydrofolate reductase and dihydropteroate in the cytosol, (Fig. 2). 
 
a. Quinine and related compounds (Fig. 3) 
Quinine, along with its dextroisomer quinidine, continues to be used for the 
treatment of severe malaria. Chloroquine (CQ) is a 4-aminoquinoline derivative of quinine 
and the most widely used antimalarial drug. It has been the drug of choice for 
uncomplicated malaria therapy and for chemoprophylaxis. Yet, its use has dramatically 
reduced due to widely spread resistance. Chloroquine works by binding with 
ferriprotoporphyrin IX in the parasite, thereby antagonizing the polymerisation of this 
toxic metabolic product into inert crystal of hemozoin [47]. Another quinine derivative, 
amodiaquine, is an available compound closely related to CQ. Other quinine-related 
compounds in common use include primaquine (specially used to eliminate the 
exoerythrocytic forms of P. vivax and P. ovale that cause relapses) and mefloquine, a 
quinoline-methanol derivative of quinine [48]. The primaquine action mechanism is 
mediated by reactive metabolites which destroy mitochondrial structure of the parasite 
[49], while mefloquine is believed to work in the same way as CQ [50].  
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Figure 3. Aminoquinolines: quinine and related compounds 
 
b. Antifolate drugs 
These drugs are a variety of dihydrofolate-reductase (DHFR) inhibitors [50] that 
arrest DNA replication (proguanil, chlorproguanil, pyrimethamine, and trimethoprim) 
and dihydropteroate synthase (DHPS) inhibitors (dapsone, sulfalene, 
sulfamethoxazole, sulfadoxine, and others) (fig. 4). Despite their use in combinations, 
parasite resistance to these drugs can develop rapidly.  
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Figure 4. Antifolate drugs 
 
c. Antibiotics 
Tetracycline and its derivatives such as doxycycline are very potent 
antimalarials and used for both treatment and prophylaxis. In areas where response to 
quinine has deteriorated, tetracyclines are often used in combination with quinine to 
improve cure rates [51, 52] and effectively reduce the duration of treatment [53]. 
Another antibiotic, clindamycin, has been used as an effective treatment of malaria 
when given twice daily for five days but it is a slow-acting drug. With a mean parasite 
clearance time of four to six days its administration in monotherapy is likely to pose a 
danger [53]. Therefore, clindamycin treatment in combination with another antimalarial 
drug is highly recommended. The combination of clindamycin (5 mg/kg Body Weight) 
with quinine (10 mg/kg Body Weight) is an efficient and attainable choice for the 
treatment of malaria. Moreover, it shortens the duration of treatment for 3 days twice 
Proguanil 
Chlorproguanil 
Pyrimethamine 
Trimethoprim 
Sulfadoxine 
Dapsone 
Sulfalene 
Sulfamethoxazole 
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daily and is not contraindicated in children and pregnant women [53, 54]. The 
combination of clindamycin and CQ is also an effective and plausible treatment even 
in high rate of CQ resistance regions though requiring a higher dose of CQ [52, 53, 55, 
56].  
 
d. Artemisinin  
In 1967, the Chinese government initiated the National Project against malaria 
under the direction project 523 office. Focus on exploration of more than 2000 Chinese 
herbs has resulted in 640 hits with probable antimalarial activity and 380 extracts 
studied against animal models of malaria. Promising results were found in Artemisia 
annua L. extracts with strong and reproducible parasite growth inhibitions. These 
activities were confirmed on animal models (mice and monkeys) and supported the 
studies which led to the isolation and identification of the active compound named 
artemisinin (qinghaosu). These remarkable results on A. annua activity against malaria 
parasite were published in 1982 [57].  
Pure artemisinin (ART) (Fig. 5) has low solubility in both water and oil but it is 
possible to administrate it orally, rectally, and intramuscularly [58]. However, for 
severe malaria patients, oral route is often not possible considering the effect of intense 
vomiting. In order to overcome this obstacle and to limit the necessity of vegetal supply, 
several semi-synthetic ART derivatives have been developed [48, 59] like the water-
soluble artesunate and the oil-soluble artemether and arteether [60]. The studies of drug 
metabolism found that ART derivatives are converted into the same active metabolite 
as artemisinin: dihydroartemisin (DHA) [61, 62]. These compounds are used in 
monotherapy for treatment of severe malaria and have shown very rapid parasite 
clearance time and fast fever resolution [48]. Artemisinins probably work by generation 
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of free radicals when Fe (II) cleaves the peroxide bond of the drug in parasitized red 
blood cells, followed by alkylation of parasite proteins [49, 63]. 
 
 
 
 
 
 
 
 
Figure 5. Artemisinin, a sesquiterpene lactone with a peroxide bridge 
 
e. Miscellaneous compounds 
Atovaquone, a hydroxynapthoquinone (Fig. 6), is an effective compound 
against CQ-resistant P. falciparum, but when used alone parasite resistance can develop 
quickly. That is why atovaquone is usually given in combination with proguanil [64, 
65]. Atovaquone targets the electron transport chain (ECT) of the mitochondrion, and 
specifically the cytocrome bc1 complex [49], while proguanil acts not only as DHFR 
inhibitor but also in a synergistic effect lowering the effective concentration at which 
atovaquone breaks down the parasite mitochondrial membrane potential [66].  
Pyronaridine was reported 100% effective in Cameroon [67] but only 63%-88% 
in Thailand [68]. Pyronaridine is an acridine-based drug with unknown mode of action, 
but could act on haemoglobin degradation, haem polymerisation, and topoisomerase-2 
activity [50].  
Dehydroartemisinin: R = H 
Artemether: R = Me 
Artesunate: R = -CO-CH
2
-CH
2
-CO
2
-
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Lumefantrine is another antimalarial compound administered in combination 
with artemether [69, 70]. Lumefantrine is an aryl-amino alcohol [71] that prevents 
polymerization of haem and free radicals to induce parasite death [72]. In order to 
prevent recrudescence, it is absorbed and cleared slowly (t1/2=3-6 days) [73] to 
eliminate residual parasite that may remain after artemether has been cleared from the 
body [72, 74, 75].  
 
 
 
 
 
Figure 6. Miscellaneous compounds 
 
f. Non-Artemisinin Combination Therapy 
A two-antimalarial combination, especially when they have different 
mechanisms of action, has the potential to inhibit the development of resistance to each 
component [48]. The combination of a 4-aminoquinoline drug (CQ or amodiaquine) 
with sulfadoxine/pyrimethamine (SP) improves the parasitological clearance 
(compared with SP alone) [76]. However, high levels of resistance against these two 
chemical series indicate that these combinations are not recommended and no longer 
used [15].  
 
 
Atovaquone Pyronaridine Lumefantrine 
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g. Artemisinin based-Combination Therapies (ACTs) 
Another combination therapy approach is artemisinin derivatives associated 
with longer half-life antimalarials [48]. These combinations have been recommended 
by the WHO as malaria front-line treatment to counter the resistance of P. falciparum 
to monotherapies and to improve treatment outcome [15]. 
Artemisinin-based combination therapies (ACTs) are the current standard 
treatment for uncomplicated malaria. Artemisinin and its derivatives (artesunate, 
artemether, dihydroartemisinin) are fast acting compounds but are rapidly cleared [15] 
(human t ½ ̴ 1 hour), and are therefore combined with slow-clearing drugs to kill 
residual parasites. The typical partner drugs include lumefantrine (human t ½ = 3-4 
days) and piperaquine (human t ½ = 8-16 days) [49]. When given in combination with 
other compounds, a 3-day course of treatment with an artemisinin compound is  deemed 
effective. Five ACTs are currently recommended by the WHO: artemether + 
lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + 
sulfadoxine - pyrimethamine, and dihydroartemisinin - piperaquine [15]. ACTs have 
supplanted the previously recommended sulfadoxine – pyrimethamine, which in turn 
replaced CQ treatments [49].  
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Table 1. ACTs recommended by WHO 
[77-80] 
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4. Artemisinin-based Combination Therapies (ACTs) in Indonesia 
The year 2004 was the beginning of ACTs use in the national malaria control program 
in Indonesia. This was due to the overwhelming burden of resistance of malaria parasites to 
previous conventional malaria drugs. This step was also in conjunction with WHO’s 
recommendation of using ACTs to fight malaria [81, 82]. 
The first ACT adopted in Indonesia was artesunate-amodiaquine as first line therapy. 
This fixed dose regimen is active against P. falciparum as well as P. vivax, safe for all ages, 
and affordable though large number of pills to be ingested is a disadvantage. Moreover, in 
places such as Papua, Lampung, and North Sulawesi or in areas with high chloroquine 
resistance, treatment failures with artesunate-amodiaquine were reported [82].  
Artemether-lumefantrine has been recently, implemented in Indonesia. In a study 
conducted by Sutanto et al. (2013), artemether-lumefantrine proved to be safe and highly 
efficacious in 59 residents of eastern Sumba Island presenting uncomplicated P. falciparum 
malaria [83]. Another study in southern Papua of Indonesia, an area with multidrug resistant 
P. falciparum also showed high cure rate (95.3%) with artemether-lumefantrine, but it was less 
responsive to P. vivax compared to other combination (43%) [84]. The disadvantages of this 
ACT are: i) it should be administered twice daily for three days, given with fatty foods, and ii) 
it is expensive. This limits the utilization of artemether-lumefantrine as second line therapy for 
P. falciparum malaria.  
Dihydroartemisinin – piperaquine (DHP) can be another option to overcome the failure 
of other combinations such as artesunate-amodiaquine [82]. Based on the data of previous 
ACTs trials in Indonesia, DHP was found to be the best combination to treat uncomplicated 
malaria in areas with multi-drug resistance. In comparison with all the existing forms of ACTs, 
a 3-day DHP is the best substitute for the Indonesian ACT program. Moreover, DHP is safe 
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and effective for both P. falciparum and P. vivax malaria. The cure rates of DHP reported for 
the treatment of P. falciparum and P. vivax were 95.2% and 92.7%, respectively. DHP has been 
used for more than 2 years in Papua, a high multi-resistance area, as first line therapy [85]. In 
2006, the national drug policy was changed and DHP became the first line treatment for any 
uncomplicated cases of all four parasite species and for treatment of malaria in the second and 
third trimesters of pregnancy [14]. 
The dosage of dihydroartemisinin is 2-4 mg/kg of body weight (BW), and 16-32 mg/kg 
BW for piperaquine. The dose of DHP must be based on body weight rather than on age 
classification, except if the weight scale is not available. 
Table 2. The dosage of DHP based on body weight classification for falciparum malaria 
[86] 
Days Treatment 
Number of tablets per days based on body weight classification 
≤ 5 kg 6 -10 kg 11-17 kg 18-30 kg 31-40 kg 41-59kg  ≥ 60 kg 
0-1 
month 
2-11 
month 
1-4 year 5-9 year 10-14 
year 
≥ 15 
year 
≥ 15 
year 
1-3 DHP ¼ ½ 1 1 ½ 2 3 4 
1 Primaquine - - ¾ 1 ½ 2 2 3 
 
 
5. Antimalarial Drug Resistance 
a. Non-Artemisinin Resistance 
The obstacle to malaria eradication is parasite resistances to antimalarial drugs. 
The WHO defines resistance to antimalarials as the ability of parasite strain to survive 
and/or multiply despite the administration and absorption of a medicine given in doses 
equal to -or higher than- those usually recommended but within the tolerance of the 
subject, with the caveat that the form of the drug active against the parasite must be 
able to gain access to the parasite or the infected red blood cells for the duration of the 
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time necessary for its normal action [15]. Malaria resistances was reported with 
chloroquine, antifolates, and atovaquone [87, 88]. 
Chloroquine resistant P. falciparum began to emerge in 1957 in South America, 
South East Asia to Africa [89]. In the end of 1980, resistances to sulfadoxine-
pyrimethamine and mefloquine settled well in Thai-Cambodia and in 2006, resistance 
to artemisinin appeared [19, 88]. Commonly, the resistance mechanism of antimalarial 
agents is mediated by multidrug resistance gene polymorphism, for example Pfmdr1 
(chloroquine, mefloquine, amodiaquine, halofantrine, lumefantrine), Pfcrt (chloroquine 
and amodiaquine), Pfdhps (sulfadoxine), and Pfdhfr (pyrimethamine and proguanil) 
[90-99]. 
Two main mechanisms of Plasmodium resistance to almost all anti-malarial 
drugs are: i) modifications in transporter genes reducing drug availability at its site of 
action or ii) modifications of the drug target by mutations in the corresponding genes 
(Table 3). For antimalarials targeting the haemoglobin digestion in the food vacuole 
two transporters are mainly involved in the resistance:  the chloroquine resistance 
transporter (Pfcrt) and the multi-drug resistance transporter 1 (Pfmdr1). Another 
possibly related transporter is the multi-drug resistance associated protein (Pfmrp) 
[100]. The mechanism of resistance for these antimalarial agents is mediated by single 
nucleotide polymorphisms (SNPs) of the genes that encode these transporters or by 
an increased number of copies of some of them [101, 102]. Modifications of the drug 
target concern more with antimalarial drugs targeting metabolic pathways, such 
inhibition of the cellular respiration and the dihydroorotate dehydrogenase (DHODH) 
involved in the pyrimidine nucleotide biosynthesis at mitochondrion level [103, 104] 
or the dihydrofolate reductase (DHFR) involved in the production of purines, 
thymidine and therefore in the DNA biosynthesis in the cytosol [105, 106]. 
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Table 3. Resistance genes in antimalarial drug 
Anti-malarial Resistance 
gene 
Main resistance mechanisms  Refs  
Class Drug 
Quinolines 
Quinine 
 
Pfmdr1/other 
 
Disruption of drug accumulation 
inside food vacuole by reducing 
propensity of the drug transporter 
PfMDR1 to bind to and transfer 
anti-malarial 
[100, 
101] 
Chloroquine Pfcrt/pfmdr1 Drug extrusion from digestive 
vacuole by mutating drug 
transporter PfCRT due to higher 
lipophilicity and negativity of the 
transporter allowing ionized 
chloroquine efflux 
[107-
109] 
Mefloquine Pfmdr1/other Reduction of parasite 
susceptibility to mefloquine by 
amplification of Pfmdr1 copies 
[96] 
Natural 
endoperoxide 
compounds and 
semi-synthetic 
derivatives 
Artemisinin 
Pfk13 Quiescence 
[22, 
24] Artesunate 
Artemether 
Antimetabolites 
Sulfadoxine - 
pyrimethamine 
Pfdhps- 
Pfdhfr 
Modification of the drug target by 
reducing inhibition of enzymatic 
activity by the drug [110] Proguanil Pfdhfr 
Other Atovaquone Pfcytb Modification of the drug target by 
disruption of cytochrome bc1 
complex 
[103] 
 
 
b. Artemisinin Resistance 
The working definition of artemisinin resistance is based on observations from 
routine therapeutic efficacy studies of ACTs and clinical trials of artesunate 
monotherapy. An artemisinin resistance area is suspected by, consecutively to an 
increased parasite clearance time, ≥ 10% of patient cases with parasites detected 3 
days after treatment with ACT and more than 10% of treatment failures on day 28 or 
42 [111].  
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In 2006, declining parasite clearance rates with ART were found, marking an 
initial detection of ART resistance. This resistance emerged in multiple locations in 
the Greater Mekong subregion (GMS) and has later triggered another resistance to 
antimalarial drugs, including partner drugs of ART such as piperaquine [112]. 
Realizing that ART resistance would be an obstacle for the malaria elimination 
program, our laboratory team (Group V, LCC-CNRS, Toulouse) reviewed the 
underlying molecular mechanism of this particular resistance to provide a conceptual 
framework of cellular network involved in parasite survival. Several cases of ART 
resistance have been reported. In 2009 in vitro studies performed on blood samples of 
patients with uncomplicated P. falciparum malaria suggested an increasing 
artemisinin failures in western and eastern Thailand, also in Cambodia, apparently 
correlated with increased artemisinin IC50 values (mean of IC50 :1.87nM, 3.18nM, and 
3.34nM respectively, compare to 1.51nM of artemisinin-sensitive clone W2 [20]. 
Dondorp’s study [19] figured out reduced in vivo susceptibility to artesunate in Pailin 
(western Cambodia) as opposed to Wang Pa (northwestern Thailand). As many as 
30% patients followed in Pailin showed 10% recrudescence of artesunate 
monotherapy, and 5% of them indicated mefloquine combination Wang Pha. This 
resistance is characterized by slow parasite clearance in vivo without corresponding 
reductions on conventional in vitro susceptibility testing, in contrast to the Noedl’s 
observation about increased IC50 values the artemisinin in regions with a high failure 
rate of artesunate-mefloquine. 
A number of recent research revealed that the resistance happened to not only 
artemisinin alone but also with its combinations, such as dihydroartemisinin-
piperaquine. In Cambodia parasite recrudescence after dihydroartemisinin-
piperaquine treatment was associated with a higher prevalence of kelch13 mutations 
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and a higher piperaquine IC50. The treatment failure was caused by both artemisinin 
and piperaquine resistance [21].  
It is well established that ART resistance is mediated by mutations of the Pfk13 
propeller which trigger a sequence of events leading parasites to enter in a quiescent 
state during the presence of ART or its derivatives; the parasite restart its cell cycle 
after drug elimination. The Pfk13 belongs to the kelch super-family of proteins and is 
likely to have a similar function to Keap 1 protein which plays an essential role in 
human in protecting against oxidative stress through an unfold protein response 
(UPR). 
A putative transcription factor (uTF) associated with K13 is probably involved 
in the parasite, such as like the human transcription factor Nrf2 normally linked to 
keap1. In unstressed conditions Nrf2, linked to keap1, is degraded in the proteasome 
by a polyubiquitination process [113]. Under stress conditions or in the case of k13 
mutations, similar to Nrf2 in human, uTF could be constitutively activated by 
inhibition of its proteasomal degradation. It was recently found that PfPI3K is a ligand 
of Pfk13. In the case of Pfk13 mutations, the PI3K ubiquitination is inhibited leading 
to an increased level of basal PI3P. The PI3P role in ART resistance is confirmed by 
PI3P transgenic expression that endows artemisinin resistance in non-mutated K13 
parasites [114]. 
The underlying molecular mechanisms linked to K13 mutations and artemisinin 
resistance have yet to be completely understood. The in vivo transcriptome analysis 
of Plasmodium falciparum revealed that artemisinin resistance, caused by single K13 
propeller mutations, is associated with increased expression of a network of molecular 
chaperones and major protein complexes belonging to the Unfold Protein Response 
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(UPR) pathways. Some of the upregulated genes of these complexes are involved in 
protein folding and repair in the endoplasmic reticulum (ER) especially BiP 
(immunoglobulin-binding protein). The misfolded proteins bind to BiP and trigger a 
cascade of events probably similar to the BIP-PERK-eIF2α pathway observed in 
mammals and leading to a limitation of global protein synthesis and a cell cycle arrest 
via cyclin dependent kinases.  
The parasite ART-induced quiescence state is characterized by a suspended 
glycolysis and associated ATP and PEP productions. However, a minimum ATP and 
PEP production is ensured by apicoplat and mitochondrion that remains active during 
the quiescence stage [115].  
Although the mitochondrial tricarboxylic acid cycle is partly down regulated, 
the transcription of proteins of the electron transport chain remains active and a FASII 
pathway is implemented in the apicoplast consecutively after a decrease in host fatty 
acid incorporations. For those reasons, quiescent parasites can be killed by drugs 
targeting the respiratory chain of the mitochondrion such as atovaquone, or its FASII 
metabolism such as haloxyfob, and triclosan. 
In conclusion, Plasmodium falciparum resistance to artemisinin and its 
derivatives is not due to a common mechanism of antimalarial resistance but based on 
the increasing ability of Pfk13-mutant parasite to restrain oxidative damages. In a 
quiescence state, even though main metabolism pathways slow down, the apicoplast 
and mitochondria keep supplying minimum energy for metabolism to resume growth 
as soon as the drug is eliminated. 
Indeed, the well-defined cellular connections between the different elements 
involved in artemisinin resistance are a prerequisite to the definition of the best 
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strategy to fight this resistance and the search for efficient drugs targeting the 
quiescence phenomenon.  
 
c. A review was published in order to present the whole cellular and molecular network of 
artemisinin resistance.  
 
L. Paloque, A. P. Ramadani, O. Mercereau-Puijalon, J.-M. Augereau, F. Benoit-Vical. 
Plasmodium falciparum: multifaceted resistance to artemisinins. 
Malaria Journal, 2016, 15(1):149. DOI: 10.1186/s12936 
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6. Medicinal Plants for New Antimalarial Drug Discovery 
Malaria control is based on different strategies, among others are developing an 
effective vaccine, eradicating mosquito-vectors and discovering new drugs [116, 117]. In fact, 
the development of vaccine proved to be very problematic. Moreover, the attempt to control 
Anopheles mosquito populations has had a limited success, although the use of insecticide bed 
nets is highly correlated to malaria death rates reduction [118]. The limitation of vaccine and 
vector control as well as the increasing resistance of malaria parasites to antimalarial drugs 
pointed the importance of the discovery of new antimalarial agents [119]. The main concern 
over antimalarial drug development, beyond the antimalarial activity, is that the drugs must be 
affordable for the population in endemic regions of developing countries [7, 120]. 
Regarding these problems, plant-derived compounds play an important role in new 
antimalarial drug discovery. The knowledge of medicinal plants by native people of malarious 
regions can initiate medicinal chemistry exploration based on specific antimalarial clinical 
data. Many plants were screened or are under evaluation for their antiplasmodial activities 
[121-123], in the image of  the discovery of quinine from Chincona bark [124] and artemisinin 
from Artemisia annua. 
When the Spanish and Portuguese began to colonize South America, they discovered 
the use of the bark of Chinchona tree by native Indians to treat fevers such as those caused by 
malaria. Tea made from the bark cured the people suffering from malaria. The main 
antimalarial compound was isolated from the bark of Cinchona succiruba (Rubiaceae) in 1820 
and identified as quinine, one of the 31 alkaloids contained in the plant [125].  
The search for new antimalarial agents continued and found qinghaosu or artemisinin, 
a sesquiterpene isolated from Artemisia annua (Asteraceae), a plant used in Chinese traditional 
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medicine to treat fevers including those provoked by malaria [126, 127]. Artemisinin has 
proven to be effective in chloroquine-resistant strains of human malaria [128]. 
Another species used as an antimalarial drug in Chinese traditional medicine is 
Dichroea febrifuga (Saxifragaceae) [129] with the active principle, febrifugine. It has been 
evaluated clinically against P. vivax and P. ovale but its liver toxicity has limited its use for 
malaria treatment [130]. The NAPRALERT natural product database has listed plant species 
from 152 genera  from popular usages for antimalarial properties in Africa, Americas, and Asia 
[131]. 
Antiplasmodial activities of plant crude extracts can be classified based on the IC50 
criteria proposed by Basco and collaborators. Good activity refers to an IC50 < 10 µg/mL, 10 < 
IC50 < 50 µg/mL is classified as moderate, 50 < IC50 < 100 µg/mL indicates low activity, and 
IC50 > 100 µg/mL is considered inactive [132, 133]. For others, inactive criteria are reached if 
the IC50 > 100 µM, 20 < IC50 < 60 µM is classified as low activity, and 1 < IC50 < 20 µM refers 
to moderate or limited activity [134]. A recent study gave another classification but with closed 
criteria. Very good activity refers to an IC50 < 2 µg/mL, 2.0 < IC50 < 5.0 µg/mL is classified as 
good, 5.1 < IC50 < 10 µg/mL indicates good to moderate, 11 < IC50 < 25 µg/mL is determined 
as weak, 26 < IC50 < 50 µg/mL is specified as very weak, and IC50 > 100 µg/mL is considered 
inactive [135].  
 
7. Indonesian Medicinal Plants for Malaria Therapy 
Indonesia is rich in medicinal plants widely used by the population for any diseases 
including malaria. Basically, the use of medicinal plants for malaria treatment is based on fever 
therapy like in South America with Cinchona or Artemisia in China. Some studies 
hypothesized that antimalarial plants may act on unique biochemical targets for protozoa [131]. 
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The ethno-botanical approach is the most common strategy for screening plant 
activities. From plants, belonging to various families, which are traditionally used for malaria 
fever therapy and naturally grow in Indonesia, five species were selected as potential sources 
of antimalarial agents due to their widely well-known use and for some of them are not well 
chemically characterized: kembang bulan (Tithonia diversifolia (Hemsl.) A. Gray), cincau 
rambat (Cyclea barbata Miers), brotowali (Tinospora crispa (L.) Hook. F. & Thomson), kayu 
kuning (Arcangelisia flava Merr), and sengkubak (Pycnarrhena cauliflora (Miers.) Diels). 
a. Kembang bulan (Tithonia diversifolia (Hemsl.) A. Gray) 
Tithonia diversifolia is a woody herb or succulent shrub locally called kembang 
bulan and also known as Mexican sunflower. It is characterized by opposite leaves, 
attenuate base, acute apex, and crenate margin. It belongs to the kingdom Plantae (plants), 
subkingdom Tracheobionta (vascular plants), superdivision Spermatophyta (seed plants), 
division Magnoliophyta (flowering plants), class Magnoliopsida (dicotyledons), subclass 
Asteridae, order Asterales, family Asteraceae, genus Tithonia, and species Tithonia 
diversifolia (Hemsl) A. Gray [136]. It is commonly used for several traditional medication 
purposes including malaria fever [137]. Its infusion is suitable for constipation, 
stomachache, indigestion, sore throat, and liver pain  [138]. Some research showed that its 
ethanolic leaf extract exhibited anti-malarial activity [139]. In addition, the ether extract 
from its aerial parts demonstrated an in vitro antiplasmodial activity (IC50: 0.75µg/mL on 
chloroquine-sensitive strain (FCA)). This finding led to extraction of active compound, the 
sesquiterpene lactone tagitinin C with 0.33µg/mL IC50 against Plasmodium FCA strain 
[140]. Moreover, in vivo study showed that the ethanol extract of T. diversifolia is active 
in vivo at 200 mg/kg BW in a malaria Swiss albino mice model [141]. 
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Figure 7. The leaves of T. diversifolia (a) and tagitinin C structure (b) 
 
b. Cincau rambat (Cyclea barbata Miers) 
Cyclea barbata (Menispermaceae) can be easily distinguished by its deltoidovate, 
hispid leaves with acuminate apex, finely mucronate acumen, and long male and female 
inflorescences with dense capitate flowers. It is in the kingdom Plantae, division 
Magnoliophyta, class Magnoliopsida, order Ranunculales, family Menispermaceae, genus 
Cyclea, and species Cyclea barbata Miers [136]. In Java, the leaves of C. barbata  are 
typically prepared in the form of jelly consumed as stomach medicine and a brew prepared 
from the dried roots is used as a prophylactic against fever [142]. It has been shown that 
C. barbata leaves had a protective effect on aspirin-induced gastric ulcer in Balb/c mice 
[143]. The alkaloid extract of C. barbata roots demonstrated both antimalarial and 
cytotoxic activities, and among the five active bisbenzylisoquinolines alkaloids that were 
isolated, the most active was cycleapeltine with ED50 of 29 and 41 ng/mL on Plasmodium  
strains D-6 and W-2 respectively [144]. Continuous studies of the alkaloidal fraction of C. 
barbata roots led to identification of two new bisbenzylisoquinoline alkaloids: (-)-2’-
a b 
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norlimacine and (+)-cycleabarbatine [145] but their antimalarial properties were not 
evaluated. 
 
 
 
 
 
 
 
 
 
  
Figure 8. The leaves of C. barbata (a) and cycleapeltine structure (b). 
 
c. Brotowali (Tinospora crispa (L.) Hook. F. & Thomson)  
Tinospora crispa (L.) (Menispermaceae) is a tropical liana (woody) with heart 
shaped large shiny green leaves and yellow coloured flowers which are fascicled [146]. 
This plant is predominant in primary rainforests or mixed deciduous forests of South East 
Asia and Africa including Thailand, Malaysia, and Indonesia [147]. It is endemic in 
several areas of Indonesia particularly in Java. This plant is part of the kingdom Plantae, 
phylum Tracheophyta, class Magnoliopsida, order Ranunculales, family Menispermaceae, 
genus Tinospora, and species Tinospora crispa (L) Hook. F. & Thomson [148]. T. crispa, 
known as brotowali in traditional folklore, is used for various therapeutic purposes such 
as treatment for diabetes, hypertension, stimulation of appetite and protection from 
mosquito bites, fever and malaria, stomachache and jaundice. An infusion of the stems is 
a b 
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prescribed as a worming, and a decoction of the whole plant is used as a general tonic 
[147, 149-151]. 
Phytochemical investigations of the stems of brotowali led to the isolation of 
aporphine alkaloid, including N-formylasimilobine, N-formylanonaine, N-
formyldehydroanonaine, N-formylnomuciferine, magnoflorine, paprazine, N-trans-
feruloyltyramine, and cytidine [152, 153]. Further investigation revealed that methanol 
extract of T. crispa displays an antioxidant activity [154-156], methanol crude extract of 
T. crispa shows antiproliferative activity [156, 157], aqueous extract possesses 
hypoglycemic effect [149], and ethanol extract and its isolated fraction stimulate murine 
macrophage cell (RAW264.7) viability and intracellular expressions of cytokines [158], 
and stem extract of T. crispa shows both in vitro antiplasmodial activity [159] and in vivo 
against P. berghei in dose-dependent manner [160]. 
 
 
 
 
 
 
 
 
 
 
Figure 9. The stem of T. crispa (a) and one of the aporphine structures, N-formylasimilobine 
2-O-β-D-glucopyranoside (b) 
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d. Akar kuning (Arcangelisia flava Merr) 
Akar kuning (A. flava) found in Sumatra, Java, Borneo, and Sulawesi in Indonesia 
is a large, woody, glabrous, dioecious liana up to 20m long. The stem is up to 5 cm in 
diameter, yellow wood, and exuding yellow sap when cut. It is a member of the kingdom 
Plantae, division Magnoliophyta, class Magnoliopsida, order Ranunculales, family 
Menispermaceae, genus Arcangelisia, and species Arcangelisia flava Merr [161]. 
Traditionally, the sap of cut stems of A. flava is drunk to treat typhoid fever and sprue 
[162], hepatitis, stomach disturbance, and malaria [163]. A. flava, also known as katola by 
the communities of Muna district in Southeast Sulawesi, is traditionally used as 
antidiarrheal and yellow fever treatment by Wawoni tribes.  
Some alkaloids yielded from A. flava are berberine, 8-hydroxyberberine, 
columbamine, jatrorrhizine, palmatine, thalifendine, dehydrocorydalmine, shobakunine,  
(-)R,R-limacine, (+)R,S-homoaromaline, and pycnarrhine [162]. A previous study 
mentioned that berberine of A. flava has antimicrobial activity [164], antioxidant and 
cytotoxic activity [165]. Its antiplasmodial activity is also figured out against P. falciparum 
with IC50 ranging from 0.4 to 8.6 µg/mL [166]. In addition, the berberine extracted from 
A. flava inhibits telomerase activity in P. falciparum as a potential target for future malaria 
chemotherapy [167]. 
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Figure 10. Stem of A. flava (a) and berberine structure (b) 
 
e. Sengkubak (Pycnarrhena cauliflora (Miers.) Diels) 
Sengkubak (Pycnarrhena cauliflora (Miers.) Diels) from West Borneo has been used 
widely by Dayak tribes as a cooking flavor and treatment for flatulence (by placing soaked 
leaves on the stomach), fever and malaria (by drinking leaf infusion). This plant can be 
found in primary or secondary forests with spatial distribution and tend to grow in clusters. 
It is a slender twining shrub and frequently climbing up on a tall tree [168]. Sengkubak 
belongs to the kingdom Plantae, phylum Magnoliophyta, class Magnoliopsida, order 
Ranunculales, family Menispermaceae, genus Pycnarrhena, and species Pycnarrhena 
cauliflora (Miers.) [148]. The bisbenzylisoquinoline alkaloid compounds of P. cauliflora, 
like obaberine, picnarine [169], are responsible for many activities including antioxidant 
and cytotoxic properties [170, 171] but the antimalarial activity has yet to be 
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experimentally proved. From the eight species in the genus Pycnarrhena, only four (P. 
australiana, P. ozantha, P. manilensis, P. longifolia) have been deeply investigated. 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The plant of P. cauliflora (a) and obaberine structure (b) 
 
All these five selected plants are naturally growing in Indonesia. T. diversifolia, C. 
barbata, and T. crispa are easily found in gardens or in cultivation centers. A. flava and P. 
cauliflora are found in forests. These species are now endangered despite the clinical interest 
of some of them, such as A. flava which has been studied for its numerous activities and P. 
cauliflora that is considered as a promising source of medicinal plants. Deforestation for 
various reasons, and limited direct economic benefits for the people are the main factors of 
their extinction. In order to confirm the antiplasmodial activity and to increase their economic 
benefit, those selected plants were collected and extracted, and their activities were investigated 
using standard in vitro assays with various parasites and human cell lines for cytotoxic studies. 
Further study on isolation and characterization of active compounds will be required before 
developing a new antimalarial drug.  
a b 
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8. Gold Complexes as Antimalarial Agents 
Metal-based therapeutic agents have become an increasingly important research effort 
toward the development of new compounds with less toxic side effects and with an 
understanding of their mechanism of action [172-176]. In particular, the use of metal containing 
drugs as antiparasitic agents has not been very much explored. The emergence of resistance to 
antiparasitic drugs induces an urgent need for new, effective, non-toxic anti-parasitic drugs. 
Moreover, an immense number of rational combinations of appropriate organic molecules 
(used in traditional medicine) with different transitional metal-drug synergism can enhance the 
activity of parental organic drugs due to bonding with the metal ion. The stabilization of the 
drug by coordination with the metal ion may be related to this activity enhancement that leads 
to a prolong contact of the drug with the organism and more efficient biological targeting. 
Furthermore, the toxicity diminution of the metal ion may occur since its complexation with 
the organic drugs makes it less available for toxic reactions [177]. 
The same approach, metal-drug synergism, has also been applied for antimalarial metal 
agent discovery. It was reported that in 1987, using the drugs primaquine and amodiaquine, 32 
metal complexes were synthesized with two of those being based on gold (III). The activity 
study proved that all compounds were active against P. falciparum as well as the parental drugs 
[178].  
Gold is among the most ancient of all metals used in medicine and its current use has 
allowed information regarding toxicological and clinical administration to become available 
along with valuable studies concerning its metabolism and molecular targets. An attempt of 
attaching gold-containing fragment to CQ showed a strong variation of the electronic 
properties. Moreover, the diversity of possible gold-ligand fragments that can be attached to 
base CQ or chloroquine diphosphate (CQDP) yields a widespread exploration of their anti-
malarial properties [178].  
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One of the CQ-metal complexes, [Au(PPh3)(CQ)]PF6 potentially inhibited the growth 
of P. berghei and was also very effective against two CQ-resistant FcB1 and FcB2 strains of 
P. falciparum. It has been documented that the activity was 5-10-fold grater than the 
corresponding CQDP, displaying that gold coordination leads to a significant enhancement of 
the activity of the parental drug against resistant parasites without any adverse reaction or 
apparent acute toxic responses observed [179]. The principal mechanism proposed for the 
antimalarial action of [Au(CQ)(PPh3)]PF6 against resistant strains of P. falciparum is the 
interaction with heme and the inhibition of β-hematin formation. Both of the enhanced activity 
and the ability of this compound to lower CQ-resistance are related to the high lipophilicity of 
the metal complex and the important structural modification of the CQ structure imposed by 
the presence of the metal-containing fragment [180]. 
 
 
 
 
 
Figure 12. Structure of [Au(CQ)(PPh3)]PF6 
 
This result then stimulates a derivatization process of CQ-Au complex by structure 
modification of [Au(CQ)(PPh3)]PF6 complex. The modification included variation of the 
phosphine ligand with the purpose of inducing changes in the electronic and steric properties, 
variation of counter anion, variation of the gold oxidation state (both Au(I) and Au(III)), and 
use of other biologically important ligands. The result demonstrates that Gold (III) complexes 
are more active than CQDP against CQ-resistant strain K1. The highest activity for this series 
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is found for complex [Au(Pet3)(CQ)]PF6, which is 5-fold more active than CQDP against CQ-
resistant strain FcB1 [178].  
Recently, another ligand widely studied for its coordination with gold complex is NHC 
(NHC = N-heterocyclic carbene). NHCs represent one of the most important classes of ligands 
in organometallic chemistry. The easy preparation of NHC-precursors has allowed an almost 
infinite access to new organometallic complexes, in which the nitrogen atoms of the azoliums 
rings can be functionalized by organic groups, organometallic moieties and biological entities 
[11]. Moreover, because of their easy preparation via Ag carbene transfer route, the interest in 
AuI-and AuIII-NHC complexes has surged in the past decade [181] and interesting biological 
activities of numerous NHC-metal complexes have been documented in several articles [182]. 
AuI-and AuIII-NHC compounds are generally readily prepared, stable to air and 
moisture, and some of them, especially dinuclear gold(I) and polynuclear gold(I)-heterometal 
species display long-lived intense photoluminescence at room temperature [181]. In particular, 
given that these ligands are extremely good σ-donors, they form strong Au-carbene bonds, 
giving stable AuI-NHC complexes that are insensitive to biologically important thiol groups. 
AuI-NHC have shown potential medical applications [183], especially as anticancer [182, 184-
187], antiarthritis [188], and antimicrobial agents [189]. It has to be mentioned that gold-based 
compounds, including some gold(I)-NHCs, show anti-mitochondrial activity with great 
specificity [183]. In addition, pharmaco-modulations of N-functionalized bis(imidazolum) 
proligands and their corresponding silver(I), gold(I) and gold(III) complexes leading to the 
second series of complexes with IC50 values up to 330nM against P. falciparum strain, without 
any hemolysis [190].  
The study by Micale and colleagues explored the possible mechanism of gold 
complexes as antimalarial agents. It was noted that the parasite enzyme Falcipain 2 (Fp2) may 
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involve in this regard. This protein is correlate to the degradation of host’s hemoglobin that 
produce significant amounts of peptide and amino acids for parasite growth. This process is 
strongly occurring at the early throphozoite stage. Although the direct correlation of gold 
compounds to Fp2 inhibition has been investigated in vitro, further findings displayed that the 
inhibition of Fp2 only represent one of the diverse mode of action of gold compounds inhibit 
P. falciparum replication [11, 191]. 
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CHAPTER II 
MATERIALS AND METHODS 
A. MATERIALS 
1. Antiplasmodial Activity of Indonesian Medicinal Plants 
a. Plants & reagents  
The parts of the medicinal plants studied here were leaves of T. diversifolia, 
leaves and stems of C. barbata, stems of T. crispa, stems of A. flava, as well as 
leaves and radixes of P. cauliflora.  
Other materials used were ethanol 70%, n-hexane, ethyl acetate, and 
methanol. 
b. P. falciparum strains and cell lines 
FcM-29 Cameroon chloroquine-resistant strain was employed for assessing the 
antiplasmodial activity, while VERO cells were used for testing the cytotoxic. 
c. Antimalarial drug controls & reagents  
We used Chloroquine (Sigma), DMSO (Sigma), RPMI-1640 (Biowest, 
France), HEPES, L-glutamine, AB+ human serum (French blood bank, EFS, 
Toulouse, France), O-type human RBC (French blood bank, EFS, Toulouse, 
France), 3[H] hypoxanthine (Perkin Elmer, France), and complete medium (MEM, 
FCS, L-glutamine, penicillin, streptomycin, NEAA 1x). 
d. Tools 
The tools employed were maceration chamber, water bath, rotary evaporator, 
glass instruments, conical tubes, centrifuge, vortex, freezer, refrigerator, CO2 
incubator, 96-well plates, cell counter (Perkin Elmer) and Class II Biosafety 
cabinet. 
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2. Antiplasmodial Activity of Gold (I) Complexes 
a. Tested compounds 
Twenty-five synthesized compounds were tested in this study consist of 
the imidazolium salts (proligands: compunds 1 – 9, and 11; zwitterionic 
proligand: compound 10) and the mononuclear gold (I) bis(NHC) complexes 
(compound 12 – 25).   
All these compounds were obtained from group V UPR 8241 LCC-
CNRS, Toulouse, France. 
b. Plasmodium falciparum strains and cell lines 
Chloroquine-resistant P. falciparum FcM-29 Cameroon strain was used 
for assessing the antiplasmodial activity while VERO cells were used for testing 
the cytotoxic. 
c. Antimalarial drugs and reagents 
   The materials used in this study were Chloroquine (Sigma), artemisinin 
(TCI), DMSO (Sigma), RPMI-1640 (Biowest, France), HEPES, L-glutamine, 
AB+ human serum (French blood bank, EFS, Toulouse, France), O-type human 
RBC (French blood bank, EFS, Toulouse, France), 3[H] hypoxanthine (Perkin 
Elmer, France), and complete medium (MEM, FCS, L-glutamine, penicillin, 
streptomycin, NEAA 1x).  
d. Tools 
The tools utilized were water bath, rotary evaporator, glass instruments, 
conical tubes, centrifuge, vortex, freezer, refrigerator, CO2 incubator, 96-well 
plates, cell counter (Perkin Elmer) and Class II Biosafety cabinet. 
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3. K13 Gene and Artemisinin Resistance 
a. Strains & reagents 
The P. falciparum strains used in this research were P. falciparum clinical 
isolates from Cambodia (Cam3.I, Cam3.II, Cam5, Cam2, CamWT) and reference 
laboratory lines (F32-TEM, F32-ART, V1/S, FCB, Dd2) provided by four 
different laboratories. In our laboratory, we conducted the research using FCB, 
Dd2, and F32 strains. 
Other materials used were RPMI-1640 (Biowest, France), HEPES, L-
glutamine, AB+ human serum (French blood bank, EFS, Toulouse, France), O type 
human RBC (French blood bank, EFS, Toulouse, France), Dihydroartemisinin 
(TCI), DMSO (Sigma), Percoll® (Sigma-Aldrich), PBS, Heparin, D-sorbitol 
(Sigma-Aldrich), immersion oil, and Giemsa stain (Diff quick®). 
 
b. Materials 
The tools utilized were Class II biosafety cabinet, CO2 incubator, water-bath, 
scale, pipette and tips, flask culture, centrifuge, conical tube, filter 0.22µM pore 
size, 48-well plates, glass slides, microscope, and counter. 
 
4. Dihydroartemisinin-Piperaquine Resistance in Kupang 
a. Materials 
The materials used were dihydroartemisinin-piperaquine tablets (Darplex), 
dihydroartemisinin (TCI), RPMI-1640 (Sigma), ACD anticoagulant, O type RBC, 
culture medium (RPMI-1640, HEPES, Gentamycin, Hypoxanthine, Albumax II, 
heat-inactivated human serum), DMSO (Sigma), immersion oil, Giemsa stain 
(Merck), syringe (Terumo), filter paper (Whatmann), K13-propeller primers, 
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dNTP (Biodynes), MgCl2, Taq DNA polymerase (Solis Biodyne), and ethidium 
bromide stain.  
 
b. Strains 
The P. falciparum strain employed in this study was P. falciparum isolates from 
malaria patients in Kupang, East Nusa Tenggara.  
c. Tools  
The tools involved were conical tubes, glass instruments, glass slides, 
microscope, counter, 48-well plates, CO2 incubator, candle jar, Class II biosafety 
cabinet, water bath, balance, pipette and tips, Duran® bottles, flask cultures, 
centrifuge, and filters 0.22µM pore size. 
 
B. METHODS 
1. Antiplasmodial Activity of Indonesian Medicinal Plants 
a. Plant collections and identification 
Tithonia diversifolia (Asteraceae; voucher specimen 007-02/L-
PB/UII/2013) was collected in Sleman District of Yogyakarta, and Cyclea barbata 
(Menispermaceae; voucher specimen 008-03/L.S-PB/UII/2013) was gathered in 
Bantul District of Yogyakarta, while Tinospora crispa (Menispermaceae; voucher 
specimen 009-03/S-PB/UII/2013) was obtained in Yogyakarta City. Meanwhile 
Arcangelisia flava (Menispermaceae; voucher specimen 010-04/S-PB/UII/2013) 
was gathered in South Borneo, and Pycnarrhena cauliflora (Menispermaceae; 
voucher specimen 011-01/S.R-PB/UII/2013) was collected in Sintang District, 
West Borneo.  
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The plants were identified in the Laboratory of Biology, Department of 
Pharmacy, Universitas Islam Indonesia, Yogyakarta, Indonesia (Herbarium of 
Laboratory of Biology, Department of Pharmacy, Faculty of Science and 
Mathematics, UII, Yogyakarta, Indonesia), and their samples were air-dried (50-
60ºC) and powdered. 
 
b. Plant extraction 
Similar to the traditional ways, the parts of the plant taken for the extraction 
included leaves of T. diversifolia, stem and leaves of C. barbata, stem of T. crispa, 
stem of A. flava, as well as stem and radix of P. cauliflora.   
Powdered samples of T. diversifolia (leaves), C. barbata (stem and leaves), 
T. crispa (stem), and A. flava (stem) were extracted by maceration in 70 % ethanol 
for 24 hours, 300 g of plant powder with 1.5 L of solvent. This process was repeated 
for two days consecutively using fresh 70% ethanol. Following 3 days re-
maceration in ethanol, the extracts were filtered and the filtrates evaporated using 
a rotary vacuum evaporator, to attain ethanol extract. Some of the ethanol extract 
were then fractionated by n-hexane by liquid-liquid separation method which 
create two separate layers (n-hexane and first ethanol layer). The n-hexane fraction 
was acquired after the n-hexane layer was evaporated. The fractionation process 
was continued by fractionated the ethanol layer using ethyl acetate (liquid-liquid 
separation) which produce ethyl acetate and second ethanol layer. Both layer was 
then evaporated separately yielded ethyl acetate fraction from ethyl acetate layer 
and fraction residue from second ethanol layer, in case there were active 
compounds left behind.  
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Contrary to previous plants, radix part of P. cauliflora was extracted by n-
hexane to attract the lipophilic compound from the plant. The filtrate then 
evaporated and become n-hexane extract. Meanwhile, the precipitate of n-hexane 
extraction was further extracted using dichloromethane to obtain dichloromethane 
extract. Then, the precipitate from previous dichloromethane extraction was 
employed for methanol extraction. The methanol extract was gained from the 
evaporation of the filtrates. 
At the end of extraction process, from each part of leaves of T. diversifolia, 
stem and leaves C. barbata, and stem of T. crispa were gained ethanol extract, n-
hexane fraction, ethyl acetate fraction, and fraction residue. Meanwhile, from stem 
of A. flava there were ethanol extract, n-hexane fraction and ethyl acetate fraction. 
Yet, for each part of stem and radix of P. cauliflora produce n-hexane, 
dichloromethane and methanol extracts. Finally, it yielded 25 extracts and fraction 
that ready for investigation its antiplasmodial activities.  
c. Reagent preparation 
To evaluate the antiplasmodial activities, the stock solutions of the extracts 
(1 mg/mL) were prepared in dimethylsulfoxide (DMSO, Sigma, France) and then 
diluted in RPMI 1640 (Biowest, France). The dilutions were checked to confirm 
that the extracts did not re-precipitate under these conditions. The extracts were 
then tested immediately after their dissolution in DMSO and RPMI, kept at 4°C 
for 3-8 days, and re-tested. The residual DMSO in the assay was 2% and this was 
evaluated individually to check that this solvent percentage had no activity on 
parasite cultures. The extract concentrations for both chemo-sensitivity and 
cytotoxic assays were 0.1µg/mL, 1µg/mL, 10µg/mL, and 50µg/mL.  
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d. Chemo-sensitivity assay 
The antiplasmodial activity was evaluated with the FcM29-Cameroon 
chloroquine-resistant Plasmodium strain and cultured continuously according to 
the Trager and Jensen method [192], in a 5% CO2 atmosphere at 37°C by 
considering the modifications previously reported [193]. In brief, the parasites 
were kept in vitro in human red blood cells and diluted in RPMI 1640 medium, 
added by 25 mM HEPES, L-Glutamine and completed with 5% human serum 
(French blood bank, EFS, Toulouse, France). The antiplasmodial activity was 
assessed similarly to what was previously reported by Desjardins et al. [194] and 
modified as follows. Extract dilutions and reference compounds were tested in 
triplicate for at least 3 times independently, in 96-well plates with cultures at 1% 
parasitaemia and 1% haematocrit. For each test, the plates of parasite culture were 
incubated with extracts or reference compounds for 48 h and 3[H]-hypoxanthine 
(Perkin Elmer, France) was added to the medium 24 h after the beginning of 
incubation [193]. The parasite growth was estimated from [3H]-hypoxanthine 
incorporation. The control parasite culture (without drug and with 2% DMSO) was 
referred to as 100% growth. The IC50 values (50 % inhibitory concentration) were 
graphically determined as concentrations versus percentage of parasite growth. 
 
e. Cytotoxic evaluation on macrophage and VERO cell lines 
The cytotoxicity tests were evaluated on macrophages and VERO cell lines 
for compounds showing the best anti-leishmanial and antiplasmodial activities, 
respectively. The evaluation of cytotoxicity by MTT assay on the J774A.1 cell line 
(mouse macrophage cell line, Sigma-Aldrich) was performed according to 
Mosmann [195] with slight modifications, and cytotoxicity on VERO cells 
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(monkey epithelial cell line, Sigma-Aldrich) was assessed using [3H]-
hypoxanthine incorporation. In short, cells (5.104 cells/mL) in 100 µL of complete 
medium were seeded into each well of 96-well plates and incubated at 37°C in a 
humidified 5 % CO2 with 95 % air atmosphere. The complete medium consisting 
of RPMI 1640 was supplemented with 10 % foetal calf serum, 2 mM L-glutamine 
and antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin) for J774A.1 
cell line and MEM with 10 % foetal calf serum, 2 mM L-glutamine and antibiotics 
(100 U/mL penicillin and 100 µg/mL streptomycin), NEAA 1X for VERO cell 
line. After 24 h incubation, 100 µL medium with various product concentrations 
and appropriate controls (DMSO and doxorubicin) were added and the plates were 
incubated for 72 h at 37°C, 5 % CO2. For cytotoxic evaluation on macrophages, 
each plate well was then microscope-examined to detect any precipitate formation 
before the medium was aspirated from the wells. One hundred µL of MTT solution 
(0.5 mg/mL in RPMI) was then added to each well and the cells were incubated 
for 2 h at 37°C. Then, the MTT solution was removed and DMSO (100 µL) was 
added to dissolve the resulting formazan crystals. The plates were shaken 
vigorously for 5 min and absorbance was measured at 570 nm with a microplate 
spectrophotometer (EON).  
For cytotoxic evaluation on VERO cells, the plates were incubated with the 
test compounds for 48 h and [3H]-hypoxanthine (Perkin Elmer, France) added to 
the medium 24 h after the beginning of the incubation [193] to estimate VERO cell 
growth. The control VERO cell culture (drug-free but with 2 % DMSO) was 
referred to as 100 % of growth. The IC50 values (50 % inhibitory concentration) 
were graphically determined as concentrations versus percentage of parasite 
growth. 
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f. Anti-Babesia activity 
 Babesia divergens (Rouen 1986 strain) was cultured continuously 
according to Précigout et al [196]. The parasites were maintained in vitro in human 
red blood cells (O±; EFS; Toulouse, France), diluted to 6 % haematocrit in RPMI 
1640 medium (Biowest, France) supplemented with 30 nM NaHCO3 and 
complemented with 10 % human AB+ serum (EFS). 
 The antibabesial activity of extracts was evaluated by the same radioactive 
micromethod as that for Plasmodium in 96-well culture plates except for the 
incubation time, which was reduced to 24 h. The drug-free control parasite 
cultures were considered as 100 % growth, and an imidocarb sensitivity control 
was included in every plate. IC50 was determined graphically from concentration 
versus percentage of inhibition curves.  
 
g. Anti-leishmanial activity on promastigote state 
 The effect of the compounds tested on the growth of Leishmania infantum 
(line MHOM/MA/67/ITMAP-263) promastigotes was assessed by Luciferase 
Assay. Briefly, promastigotes in log-phase in RPMI 1640 medium (Biowest, 
France) were supplemented with 10 % fetal calf serum (Hyclone, ThermoFischer, 
France), 2 mM L-glutamine and antibiotics (100 U/mL penicillin, 100 µg/mL 
streptomycin and 50 µg/mL geneticin (Sigma, France)) were incubated at an 
average density of 106 parasites/mL in sterile 96-well plates with various 
concentrations of compounds dissolved in DMSO or MeOH (final concentration 
less than 0.5 % v/v), in duplicate. Appropriate controls treated by DMSO, MeOH 
and amphotericin B (reference drug purchased from Sigma Aldrich) were added 
to each set of experiments. After a 72h incubation period at 24°C, each plate well 
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was then microscope-examined for any possible precipitate formation. To estimate 
the luciferase activity of promastigotes, 80 µl of each well was transferred to white 
96-well plates, Steady Glow reagent (Promega) was added according to the 
manufacturer’s instructions, and the plates were incubated for 2 min. 
Luminescence was measured in a Microbeta Luminescence Counter 
(PerkinElmer). Inhibitory concentration 50 % (IC50) is defined as the 
concentration of drug required to inhibit 50 % of the metabolic activity of 
Leishmania infantum promastigotes compared to the control. IC50 was calculated 
by non-linear regression analysis processed on dose–response curves, using 
TableCurve 2D V5® software. IC50 values are the geometric mean values 
calculated from three independent experiments. 
 
2. Antiplasmodial Activity of Gold (I) Complexes 
a. Synthesized compounds 
   All the synthesized compounds (the imidazolium salts and the mononuclear 
gold (I)-bis(NHC) complexes) have been prepared in powders and ready to be 
tested.  
b. Reagent preparation 
To evaluate the antiplasmodial activities, the stock solutions of the 
synthesized compounds (1 mg/mL) were prepared in dimethylsulfoxide (DMSO, 
Sigma, France) and then diluted in RPMI 1640 (Biowest, France). The dilutions 
were checked to confirm that the synthesized compounds did not re-precipitate 
under these conditions. The synthesized compounds were then tested immediately 
after their dissolution in DMSO and RPMI, kept at 4°C for 3-8 days, and re-tested. 
The residual DMSO in the assay was 2% and this was evaluated individually to 
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check that this solvent percentage had no activity on parasite cultures. The 
synthesized compounds concentrations for both antiplasmodial and cytotoxic assay 
were 0.1µg/mL, 1µg/mL, 10µg/mL, and 50µg/mL.   
c. Antiplasmodial assay 
The antiplasmodial activity was examined for the chloroquine-resistant 
strain FcM29-Cameroon and cultured continuously using to Trager and Jensen 
method [192], in a 5% CO2 atmosphere at 37°C, and considering the modifications 
previously reported [193]. In brief, the parasites were kept in vitro in human red 
blood cells and diluted in RPMI 1640 medium, added by 25 mM HEPES, L-
Glutamine and completed with 5% human serum (French Blood Bank, EFS, 
Toulouse, France). The antiplasmodial activity was assessed similarly to what was 
previously reported by Desjardins et al. [194] and modified as follows. Synthesized 
and reference compounds were tested in triplicate at least 3 times independently, 
in 96-well plates with cultures at 1% parasitaemia and 1% haematocrit. For each 
test, the plates of parasite culture were incubated with synthesized or reference 
compounds for 48 h and 3[H]-hypoxanthine (Perkin Elmer, France) was added to 
the medium 24 h after the beginning of incubation [193]. The parasite growth was 
estimated from [3H]-hypoxanthine incorporation. The control parasite culture 
(without drug and with 2% DMSO) was referred to as 100% growth. The IC50 
values (50% inhibitory concentration) were graphically determined as 
concentrations versus percentage of parasite growth. 
d. Cytotoxic evaluation on VERO cell lines 
The cytotoxicity tests were performed on VERO cell lines for compounds 
showing the best antiplasmodial activities. The evaluation of cytotoxicity on 
VERO cells (monkey epithelial cell line, Sigma-Aldrich) was assessed using [3H]-
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hypoxanthine incorporation. In short, cells (5.104 cells/mL) in 100 µL of complete 
medium were seeded into each well of 96-well plates and incubated at 37°C in a 
humidified 5% CO2 with 95% air atmosphere. The complete medium consisting 
MEM with 10 % foetal calf serum, 2 mM L-glutamine and antibiotics (100 U/mL 
penicillin and 100 µg/mL streptomycin), NEAA 1X.  
The plates were incubated with the test compounds for 48 h and [3H]-
hypoxanthine (Perkin Elmer, France) added to the medium 24 h after the beginning 
of the incubation [193] to estimate VERO cell growth. The control VERO cell 
culture (drug-free but with 2% DMSO) was referred to as 100% of growth. The 
IC50 values (50% inhibitory concentration) were graphically determined as 
concentrations versus percentage of cell growth. 
 
3. K13 Gene and Artemisinin Resistance 
a. Continuous culture of P. falciparum 
The artemisinin resistance was assessed against various clinical isolates 
(Cam3.I, Cam3.II, Cam5, Cam2, and CamWT) and laboratory lines (F32 TEM, 
V1/S, FCB, and Dd2). All strains were cultured continuously according to Trager 
and Jensen method [192], in a 5% CO2 atmosphere at 37°C, taking into account 
the modifications previously described [193]. The parasites were briefly 
maintained in vitro in human red blood cells and diluted in RPMI-1640 medium, 
supplemented with 25 mM HEPES, L-Glutamine and completed with 5% human 
serum (French Blood Bank, EFS). 
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b. Reagent preparations 
1) Stock and test solution of Dihydroartemisinin 
Dihydroartemisinin (DHA) stock solutions were prepared in DMSO to 
obtain 1mg/mL of stock solution. To have a 200µg/mL (700nM) of stock 
solution, the initial stock solution 1mg/mL was diluted 5-fold in DMSO. A 
total of 50 µL aliquots of 700nM stock solution was stored in sterile 1.5 mL 
micro centrifuge tubes at -20°C. For DHA test solution, 20 µL of DHA 700nM 
stock solution was added to 2 mL of culture medium. 
 
2)  Control solution of Dimethylsulfoxide (DMSO)  
Dimethylsulfoxide (DMSO) control solution was prepared by adding 20 
µL of DMSO to 2 mL of culture medium. 
3) Percoll® solutions 
Percoll® solutions were prepared at room temperature, in a Class II 
biosafety cabinet, using sterile reagents. Nine volumes of Percoll® (Sigma-
Aldrich) were mixed with one volume of 10x PBS to make a Percoll® 90% 
solution (stored at 4°C, up to 2 months). For RSA assay, 7.5 volumes of 
Percoll® 90% solution were mixed with 1.5 volumes of heparinized RPMI-
1640 (freshly prepared 15 µL heparin mixed with 10 mL RPMI-1640) to 
obtain a Percoll® 75 % solution prepared directly prior to the assay. 
4) Sorbitol solution 
A total of 50 grams of D-sorbitol (Sigma-Aldrich) was dissolved in 1L 
of distilled water resulting in a 5% D-Sorbitol solution. Using a 0.22 µM filter, 
the homogenized solution was sterilized and stored at 4°C (up to 1 year). 
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c. In vitro RSA assay 
These assays were carried out as previously described [197], with minor 
modifications. In summary, 10-15 mL parasite cultures were synchronized 1-2 
times using 5% sorbitol (Sigma-Aldrich). Synchronous multinucleated schizonts 
were incubated in RPMI-1640 containing 15 units/mL sodium heparin for 15 min 
at 37°C to disrupt agglutinated erythrocytes, concentrated over a gradient of 75% 
Percoll® (Sigma-Aldrich), washed once in RPMI-1640, and incubated for 3 hours 
with fresh erythrocytes to allow time for merozoite invasion. Cultures were then 
subjected again to sorbitol treatment to eliminate remaining schizonts. The 0-3 
hours of post-invasion rings were adjusted to 1% parasitemia and 2 % hematocrit 
in 1 mL volume (in 48-well plates) and exposed to 700nM DHA or 0.1% DMSO 
(solvent control) for 6 hours. Duplicate wells were established for each parasite 
line ± drug. As much as 1 mL of the cultures was then transferred to 15 mL conical 
tubes and centrifuged at 1600 rpm for 5 min to pellet the cells, and the supernatants 
were carefully removed. As a washing step to remove drug, 9 mL of culture 
medium was added to each tube, the cells were re-suspended and centrifuged, and 
the medium was aspirated. Fresh lacking drug medium was then added to the 
cultures, and this mixture was returned to standard culture conditions for 66 hours. 
Parasite viability was assessed though microscopic examination of 
Giemsa-stained thin blood smears by counting the parasites developed into second-
generation rings or trophozoites with normal morphology. To obtain a 
homogenous smear for all slides, the culture was re-suspended, transferred into an 
Eppendorf tube, and briefly centrifuged (2000 rpm for 30 seconds). Exactly 2 µL 
of the pellet was then used for each smear. Parasitemias were calculated from a 
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total of at least 40,000 erythrocytes per assay. Slides were read from the two 
duplicate wells per assay by two separate microscopists, each of them was 
examined for at least 10,000 erythrocytes per slide. In the case of more than 20% 
discrepancy in parasite counts, the slides were further examined by a third 
microscopist. The percentage of survival was calculated as the parasitemia in the 
drug-treated sample divided by the parasitemia in the untreated sample multiplied 
by 100.  
% survival =  
drug treated sample parasitemia (DHA wells)
untreated sample parasitemia (DMSO wells)
 ×100 
The artemisinin resistance was described as ≥ 1.5% of survival percentage.  
 
4. Dihydroartemisinin-Piperaquine (DHP) Resistance in Kupang 
a. Ethics approval submission 
The study protocol and informed consent have been approved by the 
Medical and Health Research Ethics Committee of the Faculty of Medicine, 
Gadjah Mada University, Yogyakarta (ref number KE/FK/222/EC). Therefore, 
the entire process of the study has been conducted under ethical considerations.   
 
b. Study population 
The population of this study covered several areas in Kupang East Nusa 
Tenggara which has a high case incidence (HCI) based on the Annual Parasite 
Incidence (API). The samples followed the inclusion criteria, such as patients 
diagnosed for non-complicated malaria caused by particularly P. falciparum 
(slide-confirmed malaria), those having fever or history of fever 48 h prior to 
presentation, patients seeking treatment in primary health center or district referral 
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hospital, and those agreeing to sign the informed consent and follow the study. 
The exclusion criteria were pregnant or lactating women, children under 5 kg, 
anyone already taking malaria treatment for 4 weeks beforehand, diagnosed for 
complicated malaria (co-infection), infected by other Plasmodium species than P. 
falciparum, having signs of severe malaria, severe malnutrition, serious 
underlying disease (renal, cardiac, or hepatic), or known to be allergic to the 
research drugs. 
 
c. Drug administration and follow-up 
The dihydroartemisinin-piperaquine (DHP) was administered 3 times 
daily for 3 days with a dosage of 2-4 mg/kg of body weight (BW) of 
dihydroartemisinin and 16-32 mg/kg BW of piperaquine. Subsequent follow up 
appointments were scheduled for days 2, 3, 7, 14, 21, 28, 35, and 42; in addition, 
the blood smear was examined during the follow-up periods and collected on filter 
paper for DNA extraction. During the follow-up visits, patients were asked about 
the general condition of well-being as well as open questions about possible 
adverse effects that might occur since the last visit and examined by the research 
physicians. 
 
d. Parasite isolate preparation 
Venous blood was collected aseptically into an ACD anticoagulant tube 
from the patients before a treatment administration (H0). Using a drop of blood, 
parasitemia evaluation was performed by a Giemsa-stained thin blood smear. 
Following parasitemia determination, blood centrifugation (800g for 5 minutes) 
separated RBC pellet from the plasma and buffy coat. The RBC pellet was then 
67 
 
 
 
washed using RPMI (20 mL of RPMI, centrifugation at 800 g for 5 minutes and 
removal of supernatant, consecutively) for 6-8 times, preparing infected RBCs to 
be processed for ex-vivo RSA.  
 
e. The ex-vivo Ring-stage Survival Assay (RSA) 
The ex-vivo Ring-stage Survival Assay (ex-vivo RSA) was performed on 
the parasite isolates freshly collected from patients with uncomplicated P. 
falciparum malaria. The parasites were exposed to 700nM dihydroartemisinin 
(DHA) for 6 hours – approximating their drug exposure in patients treated with 
artemisinin – and their survival was assessed 72 hours later [198]. 
To perform the ex-vivo RSA, ≥ 0.5% parasitemia was required. The 
parasite solution was prepared by adding 50µL of infected RBCs to 2.5 mL of 
culture medium. If the parasitemia was > 1%, pellet was diluted with uninfected 
RBCs to obtain 0.5-1% parasitemia and with culture medium to obtain 2% 
hematocrit. A thin smear was made for determining initial parasitemia. The culture 
medium consisted of RPMI-1640 medium, HEPES, gentamicin, hypoxanthine, 
Albumax II, and heat-inactivated human serum. 
 In a 48-well culture plate, 900 µL of parasite solution was transferred to 
each well and added with 100 µL of DMSO solution in the control well or 100 µL 
of DHA solution (700nM) in the treatment well. The 48-well culture plate was 
maintained in an incubator under 370C, humid atmosphere, 5% O2, 5% CO2, and 
90% N2 for exactly 6 hours. After 6 hours, the contents of each well were 
transferred into 15mL centrifuge tubes for a following centrifugation at 800g for 
2 minutes. Then, 12 mL of pre-warmed RPMI was added for washing the RBCs 
pellet prior to a transfer into new wells in the 48-well culture plate with 1 mL of 
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culture medium to resuspend the pellet. The new 48-well culture plate was 
maintained in an incubator (370C, humid atmosphere, 5% O2, 5% CO2, and 90% 
N2) for 66 hours. Finally, the Giemsa-stained thin smear of each well was made at 
the end of incubation and determined for the percentage of survival under a 
microscope examination. 
 At 100x magnification in immersion oil, the number of infected RBCs 
containing viable parasites were counted in a total of 10,000 RBCs. Only viable 
parasites were scored; so, vacuolated and pyknotic forms were not considered. To 
determine the proportion of viable parasite (% survival), the parasitemia of DHA 
exposed was compared to the parasitemia of non-exposed (DMSO). 
 The ex-vivo RSA would be performed also at any days of treatment failure 
emerging during the follow-up. 
 
f. Sequencing the K13-propeller domain 
The molecular marker the PfK13-propeller domain was amplified using the 
following primers: for the primary PCR (K13-15’-cggagtgaccaaatctggga-3’ and 
K13-4 5’-gggaatctggtggtaacagc-3’) and the nested PCR (K13-2 5’-
gccaagctgccattcatttg-3’ and K13-3 5’-gccttgttgaaagaagcaga -3’), one µL of DNA 
was amplified with 1µM of each primer, 0.2 mM dNTP (Solis Biodyne), 3 mM 
MgCl2 and 2U Taq DNA polymerase (Solis Biodyne), using the following cycling 
program: 5min at 94oC, then 40 cycles of 30 s at 94oC, 90 s at 60oC, 90 s at 72oC 
and final extension of 10 min at 72oC. For the nested PCR, 2 µL of primary PCR 
products was amplified under the same conditions, except for the MgCl2 
concentration (2.5 mM). The PCR products were detected using 2% agarose gel 
electrophoresis and ethidium bromide staining. Meanwhile, the double-strand 
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sequencing of PCR products was performed using Macrogen, and the sequences 
were then analysed using MEGA5 software version 5.10 to identify specific SNP 
combinations. 
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CHAPTER III 
RESULTS 
 
This chapter points out various strategies investigated for malaria elimination, 
particularly in Indonesia. The first part is dedicated to discover new antimalarial drugs either 
from Indonesian medicinal plants or with synthesis of organometallic compounds. Moreover, 
as artemisinin resistance has emerged in South-East Asia, it is important to confirm the major 
role of molecular markers involved in this resistance. Defined by reverse genetic of the 
mutation involvement of Pfk13 gene in this resistance, the study of its spread in South East 
Asia regions is used to monitor the possible appearance of artemisinin resistance in malaria 
endemic areas in Indonesia. 
A. Antiplasmodial Activity of Indonesian Medicinal Plants 
 
1. Results obtained 
The emerging resistance of artemisinin, the basis of recent first-line combination therapy, 
has threatened the global effort to reduce malaria caused by P. falciparum. Moreover, there are 
no current antimalarial drug to replace artemisinin, hence discovering new antimalarial drug is 
inevitable.  One of the strategies to find new antimalarial agents is the in vitro evaluation of 
crude extracts activities of medicinal plants against P. falciparum strains. Indonesia’s rich 
biodiversity features medicinal plants used traditionally for a variety of disease treatments, 
including malaria. In cooperation with CNRS - LCC in Toulouse, France, the Faculty of 
Medicine of Universitas Gadjah Mada conducted the assessment of antiplasmodial activities 
of five medicinal plants: T. diversifolia, C. barbata, T. crispa, A. flava and P. cauliflora. These 
plants were selected due to their popularity as a fever therapy among Indonesians and because 
they naturally grow in Indonesia. In addition, some of these plants possess not only medicinal 
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advantages but also economic benefits, such as C. barbata prepared for drinks and sold in 
sidewalks. In contrast, some of them offer limited information on their medicinal and economic 
benefits, such as P. cauliflora, making people ignore their cultivation and the plants become 
endangered.  
This France-Indonesia collaboration aimed to conduct a standardized study targeting 
antiplasmodial activities of these extracts. In addition, since Plasmodium has similar 
biochemical pathways with Babesia, another apicomplex parasite, we intended to discover 
shared active compounds on these two close pathogens. Moreover, as malaria patients can also 
be co-infected by leishmaniasis in areas where the two parasites coexist, especially in tropical 
and subtropical countries such as in South America as one of the endemic regions [9], it was 
also interesting to assess the antileishlaniasis activities of the selected extracts. This study was 
completed by an assessment of the cytotoxicity on mammalian cells to determine the specificity 
of their activities. 
Our team gathered the plants from different areas in Indonesia and identified them in 
the Biology Laboratory of the Pharmacy Department of Universitas Islam Indonesia in 
Yogyakarta. A maceration process with various solvent polarities was utilized to extract the 
active compounds of the plants. The chloroquine-resistant strain of P. falciparum FcM29-
Cameroon was selected to evaluate the antiplasmodial activity of these various extracts 
according to Desjardins’s method with slight modifications. The same assay method was used 
for anti-babesial activity, except that B. divergens was cultured following the method by 
Précigout et al [196]. The anti-leishmanial activity was examined by a luminescent assay based 
on luciferase activity on L. infantum blood stage preceding the macrophage invasion 
(promastigotes). For the extracts with the best antiplasmodial and anti-leishmanial activities, 
cytotoxicity tests were conducted against macrophages and VERO cell lines using MTT assay 
and [3H]-hypoxanthine incorporation, respectively. 
72 
 
 
 
The results figured out that, among the 25 crude extracts and fractions, seven indicated 
promising antiplasmodial activities (IC50 < 5µg/mL) [135]:  T. diversifolia ethanol extract and 
ethyl acetate fraction, A. flava ethanol extract, N-hexane and ethyl acetate fractions, P. 
cauliflora radix part dichloromethane, and methanol extracts. Additionally, these best 
antiplasmodial extracts were then tested on the VERO cell line to investigate the specificity of 
their activity which was then translated into selectivity index (SI) as a ratio between 
cytotoxicity and activity (antiplasmodial activity, in this regard). However, only A. flava and 
P. cauliflora radix dichloromethane extracts featured high selectivity against VERO cell lines 
(> 50µg/mL).  
Tithonia diversifolia or locally known as kembang bulan was active against P. 
falciparum (ethanol extract and ethyl acetate fraction), but their cytotoxic values were similar, 
with less than 1 selectivity index. This low selectivity index (SI) indicated that this plant offers 
limited interest for further investigation although several previous studies demonstrated its 
activity. The ether extract of aerial parts showed in vitro antiplasmodial activity (IC50: 0.75 
µg/mL against CQ-sensitive strain FCA) which led to extraction of active compound, tagitinin 
C, a sesquiterpene lactone possessing 0.33 µg/mL IC50 against FCA [140]. Not only in vitro 
activity, T. diversifolia  was also reported on its in vivo antiplasmodial activity in a mouse 
malaria model at concentration of 200 mg/kg [141].  
Meanwhile, with the IC50 around 3 µg/mL, A. flava (also known as kayu kuning) ethanol 
extract, n-hexane and ethyl acetate fractions displayed a good antiplasmodial activity. In 
addition, their cytotoxicity against VERO cell showed high selectivity level (SI: >50). Based 
on literature, the antiplasmodial activity of A. flava extract has been published with the range 
of IC50 from 0.4 to 8.6 µg/mL against P. falciparum [166] and one of its active compounds, 
berberine, has been proved to inhibit telomerase activity of P. falciparum [167]. The result of 
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this study supports those previous findings with additional information about selectivity of the 
extracts. 
Sengkubak or P. cauliflora, a medicinal plant that has not been widely explored, 
demonstrated the best IC50 values on its dichloromethane and methanol extracts, especially 
from radix part (3.3 µg/mL for both solvents) even though the high selectivity index only 
showed for the radix dichloromethane extract (SI:>15). This plant was reported having 
antioxidant [171] and cytotoxic activity [170] with bisbenzylisoquinoline alkaloids (obaberine 
and pycnarrhine) as active compounds [169]. Yet, no study has revealed its antiplasmodial 
activity to date. This plant then appears particularly promising and deserves further study since 
its active compound, bisbenzylisoquinoline alkaloids, has been reported to have antiplasmodial 
activity [199]. 
Unexpectedly, even though it is commonly used for traditional malaria treatment, extract 
and fraction from C. barbata (stem and leaf) or T. crispa (stem) did not show antiplasmodial 
activity. After 3 independent experiments, its IC50 values were constantly beyond 5 µg/mL, a 
threshold to classify good activity of the extract. Previous studies found that 
bisbenzylisoquinoline alkaloids (tetrandrine, limacine, thalrugosine, homoaromaline, and 
cycleapeltine extracted from the root of C. barbata have both cytotoxic and antimalarial 
activities [200].  Other report also stated that those bisbenzylisoquinoline alkaloids 
demonstrated high antiplasmodial activity [201, 202]. On the other hand, a study on T. crispa 
reported its antiplasmodial activity of the stem against P. berghei [203] and in vitro activity 
from methanol stem extract with the IC50 value of 0.8 mg/mL [159]. That IC50 value correspond 
to the result of this study, which indicate low interest in pharmacological activity. 
Eight extracts also displayed anti-babesial activities with IC50 values ranging from 1.2 
to 14.1 µg/mL, with 3 of them close to the control babesial inhibitor, imidocarb (0.5µg/mL). 
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With a good selectivity index A. flava extract and fractions showed that an antiplasmodial 
activity can also be coupled with an anti-babesial activity.  
Concerning the extract assays on L. infantum, only 3 had IC50 values less than 50µg/mL: 
the ethyl acetate fraction of T. diversifolia, and, dichloromethane and methanol fractions of P. 
cauliflora radix (IC50 21.9, 1.7 and 4.4 µg/mL, respectively). The results showed that P. 
cauliflora radix methanol extract was active against P. falciparum, Babesia and L. infantum at 
similar concentrations and relatively low indexes of selectivity, suggesting a global cytotoxic 
effect in contrast to the dichloromethane fraction at which the cytotoxicity was low on VERO 
cells. 
In conclusion, extracts or fraction with a good antiplasmodial activity can be positively 
correlated to a good and specific antibabesial activity. Among the most active extracts against 
P. falciparum, only dichloromethane and methanol extract of P. cauliflora were active against 
L. infantum. The specific anti-parasite activities of some extracts were confirmed by their weak 
cytotoxicity on VERO cell line. These particular extracts need an in-depth phytochemical 
assessment in order to identify and characterize the active compounds either to standardize 
plant preparations or to chemically develop new anti-parasitic compounds as detailed in the 
article below submitted for publication.  
2. Corresponding publication 
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B. Antiplasmodial Activity of Gold(I) Complexes 
1. Results obtained 
Synthetic molecules are part of another approach to discover new antimalarial drugs. 
Organometallic compounds containing metal complex that acts as pro-drugs and can have an 
enhanced efficacy (such as ferrocene with CQ leading not only to ferroquine but also gold and 
ruthenium complexes). NHCs, as the most important ligands in organometallic chemistry, are 
easy to prepare and able to stabilize the complexes. Biomedical applications of gold complexes 
based on NHCs are beginning to unfold. In particular, these ligands form strong Au-carbene 
bonds, giving stable AuI-NHCs complexes that are insensitive to biologically important thiol 
groups. AuI-NHC have shown potential medical applications [183], especially as anticancer 
[182, 184-187] and antimicrobial agents [189]. It has to be mentioned that gold-based 
compounds, including some gold(I)-NHCs, show anti-mitochondrial activity, a promising 
mode of action to fight cancer. Their antitumor activity may stem from the lipophilic and 
cationic properties, allowing their accumulation in mitochondria of tumor cells with great 
specificity [183]. It has also been demonstrated that the combination of metal complexes with 
NHCs can exhibit interesting biological activities against such parasitic infections as malaria 
and leishmaniasis [190, 204-206].  
Our previous study proved that mononuclear cationic gold(I) complexes containing 
aromatic amino-functionalized NHC have in vitro antiplasmodial activity against FCM29-
Cameroon [190]. This finding is exploited in this present study by further studies and fine 
tuning of the main structure of these organometallic molecules in relation to their 
antiplasmodial activity or against other parasites as well as studying the activity of new 
complexes. 
To achieve the objective of investigating the influence of the different structure 
modulations on biological activities, synthesized proligand imidazolum salts (compounds 1-
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11) and mononuclear gold(I) complexes (compounds 12-25) were evaluated for its activity 
against CQ-resistant P. falciparum strains (FcM29-Cameroon and FcB1-Colombia) and put in 
comparison with CQ and artemisinin. These synthesized compounds (Fig. 12-14) were a series 
of N-, O- or S-functionalized proligands and their corresponding mononuclear cationic, anionic 
or neutral gold(I) bisNHC complexes. The most active compound would be investigated on its 
cytotoxic activity on Vero or McF7 cell lines. 
Compound 1 (2-chloroquinoline) is an imidazolum precursor that is functionalized by 
nitrogen containing heterocycles quinoline. An aryl directly attached to its azolium ring 
generates compound 2 and 3. As another imidazolum precursor, compound 4 is containing 
bipyridine. Meanwhile, compound 5 – 8 are the amine functionalized imidazolium salt combine 
with alkyl- (metyl for compound 5 and n-butyl for 6) and arylimidazoles (benzyl for compound 
7 and mesityl for 8). 
Using those imidazolium precursors, gold(I) complexes are developed. Compound 1 
generates compound 12, 2 to 14, 3 to 15, 4 to 16, 5 to 18, 6 to 19, 7 to 20, and 8 to 21. Meanwhile 
compound 13 and 17 are neutral form of the complexes. In addition, imidazolium salt 
compound 9, 10, 11 are precursor for compound 22 and 23; 24; and 25 respectively. 
Assessed against P. falciparum strains FcM29-Cameroon and FcB1-Columbia, 
different compounds (4, 5, 6, 18, 19) indicated various results allowing relationship structure 
activity studies. As cationic molecule, the imidazolium salts (proligand 1 and 4-11) were 
inactive while proligands 2 and 3 showed IC50 value of 1.4 and 1.5 µM respectively. Tested 
gold(I) complex compounds (12, 15-16 and 19-22) expressed improved activities compared to 
imidazolium salt demonstrating that gold cation plays an important role in antiplasmodial 
activity. A prior study suggested that one of the possible mechanisms of action of gold 
compounds is based on the reversible inhibition of the parasite enzyme falcipain 2 (Fp2) 
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involved in hemoglobin digestion. As a cysteine protease of P. falciparum, Fp2 will provide a 
significant quantity of peptides and amino acids from human hemoglobin degradation for 
parasite growth. Moreover, it is also characterized as a validated target for antimalarial drug 
discovery [191].  
It has been demonstrated that cationic compounds can enhance antiplasmodial activities 
by positively facilitating the accumulation of molecules inside the parasite, the global charge 
thus become the key factor. It has been shown that the cationic Au(I) bis (NHC) species had 
the best results against P. falciparum with sub-micro molar IC50s  for some of them were 2.1 
µM (19), 0.48 µM (20), 0.21 µM (21), and 0.32 µM (22). On the contrary, moderate activities 
were obtained with neutral complexes (compounds 13, 17 and 23 with IC50 between 4.1 and 
6.6 µM) as well as anionic compounds 24 and 25 (IC50 5.6 µM and 3.7 µM, respectively). 
The NHC carbenic ligand not only acted as a transporter of metal center to its target but 
also affected antiplasmodial efficacy proven by the gold(I) series 18-21 reducing IC50 values 
from methyl- (18: 22 µM) to mesityl – substitutes (21: 0.21 µM). The complex 21, the most 
active compound against P. falciparum, had lipophilic properties allowing to penetrate into the 
parasite through its different membranes.  
Another compound with nitrogen-functionalized NHC revealed that a quinoline moiety 
in the complex had a lower antiplasmodial activity (compound 13, IC50: 5.2µM) than 
compounds 12 and 14 (IC50 1.1µM) which had methyl and mesityl as non-functionalized 
substituents. Compound 15 (IC50: 0.47µM) with a thioether group demonstrated an increased 
antiplasmodial activity, and a methylthiophenyl group was responsible for the antiplasmodial 
potency of compound 22 (IC50: 0.32µM).  
The most active compounds (15, 16, 20, 21 and 22) were also tested for their specificity 
against mammalian cell lines. The selectivity index was ranked from 0.9 to 18 with the highest 
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selectivity index for compound 21. These findings supported previous studies of cancer cell 
lines (IC50 < 1µM) and non-tumor cell lines (IC50 > 5µM) [204]. It means that complex 21 is 
particularly active against P. falciparum or several cancer cell lines but having limited effects 
on normal human cells.    
It is noted that cationic lipophilic gold(I)-NHC complexes are the most active 
compounds against P. falciparum compared to both neutral and anionic compounds. The 
lipophilicity property and presence of nitrogen or sulfur atoms in the ligands were likely to be 
responsible for the antiplasmodial activity as detailed in the following published article.  
 
2. Corresponding publication 
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C. Gene Pfk13 and Artemisinin Resistance 
a. Results 
Based on the identification of a candidate marker of artemisinin resistance from the 
highly artemisinin resistant laboratory strain F32-ART, a study conducted by Ariey et al. led 
to precision of the molecular marker of this resistance in isolated resistant parasites from 
patients in Cambodia. It was demonstrated that specific mutations in the K13-propeller are 
strongly correlated with artemisinin resistance, both in vitro and in vivo. Three-high frequency 
mutant alleles with high survival rates determined by RSA0-3h wereY493H, R539T, and C580Y 
[24] and long parasite clearance half-lives (>5 hours) in patients [207]. On the other hand, first 
K13 mutant allele that have been observed was M476I. It was found in Tanzanian F32 parasites 
that experienced long-term artemisinin pressure in vitro for over 5 years, yielding the F32-ART 
line [22].    
Therefore, the molecular mechanism of this resistance would be defined by determining 
the impact of Pfk13 gene mutations on the levels of artemisinin resistance in clinical isolates 
in lab strains and assessing the role of individual polymorphism in certain types of genetic 
backgrounds. The study was a collaborative work between CNRS-LCC- (Dr F. Benoit-Vical, 
Toulouse, France), Columbia University College of Physicians and Surgeons (Dr D. Fidock, 
New York, USA), Institut Pasteur Paris (Dr O. Mercereau-Puijalon, France), and Institut 
Pasteur du Cambodge (Dr D. Ménard, Cambodia). 
Zinc-finger nucleases (ZFNs) were successfully used to modify K13 genetically 
culture-adapted Cambodian isolates and the well-known reference lines of P. falciparum (Dd2, 
FcB, V1/S, F32-ART). ZFNs promoted double-stranded break in K13 genomic target locus 
followed by DNA resection and repair, allowing to capture the mutations transferred by 
pZFNK13-hdhfr plasmids.  
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Assessment of mutations insertion or removal was conducted through RSA0-3h assay on 
parenteral and edited parasites. The 0-3 hours of post-invasion ring (1% parasitemia, 2% 
hematocrit) were exposed to 700 nM Dihydroartemisinin (DHA) for 6 hours. To remove drug, 
a washing step was employed by adding culture medium and followed by returning fresh 
medium without drug to culture conditions for 66 hours. The survival rate was determined by 
assessing parasite viability using microscopic examination of Giemsa-stained thin blood 
smears.  
Higher survival rates were obtained from Cambodian isolates (Cam3.IR539T and 
Cam3.IIR539T) containing the R539T mutation. In contrast, significantly lower survival rates 
were found when the R539T mutation was removed from the isolates, restoring therefore the 
wild type allele (Cam3.Irev and Cam3.IIrev). Same results were observed with I543T mutation 
removal (43% survival rates in Cam5I5435T versus 0.3% in Cam5rev) and C580Y mutation 
removal (13% survival rates in Cam2C580Y versus 2.4% in Cam2rev). 
Moreover, survival rates increased when K13 mutation was introduced to wild type 
carrying parasite (CamWT, Cam3.IIrev, V1/S, F32-TEM and FcB). In details, C580Y to 
CamWT (0.6% survival rate in CamWT to 8.9% in CamWTC580Y), Cam3.IIrev and C580Y 
(0.7% in Cam3.IIrev and 24.1% in Cam3.IIC580Y), R539T to V1/S (0.3% in V1/S versus 20.7% 
in V1/SR539T) showed significant increase, while it was moderate with M476I for F32-TEM 
and C580Y for FcB. 
To examine the differences of K13 mutations in ART resistance level, M476I, R539T, 
I543T were inserted in the Dd2 reference line resulting in higher survival rates than when 
Y493H and C580Y were introduced. Although C580Y mutation was predominant in 
Cambodia, Laos and Vietnam [28], the associated survival rates increased modestly. The 
variety of survival rates obtained after the insertion of the mutation C580Y into different clones 
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like Dd2, FcB, and three Cambodian isolates indicated the influence of the parasite genetic 
background. This phenomenon was also found in other Asian countries, but not in the most 
endemic malaria region, Africa, because the Cambodian parasite has restricted genetic 
admixture that contains distinctive K13 mutation as opposed to the one in Africa.  
Latest publications determined that non-synonymous K13 mutations were located in 
Southeast Asia to China with proportion ranging from moderate (10-20%) to fixed (> 95%), 
and were confirmed to be associated with artemisinin resistance. Based on geographical 
localization, there are two areas harboring specific individual mutations including Cambodia, 
Vietnam, and Laos for C580Y, R539T, Y493H, and I543T and Thailand, Myanmar, and China 
for F446I, N458Y, P574L, and R561H. K13 mutations were uncommon in Africa, but were 
thought to be found in few African countries (the proportion ranging from 3.0% to 8.3%). 
Further identifications showed that there was no Asian K13 mutation allele in African samples. 
Moreover, the fourth most frequent mutant allele in Africa observed in one sample from 
Thailand, A578S, was clearly defined as not correlated to artemisinin-resistance. It is suggested 
that for the moment, no ART-resistance was reported in Africa. Furthermore, no Asian ART-
resistant alleles were found in Africa isolates [28].  
It has been demonstrated that K13-propeller mutations lead to ART resistance in vitro 
and are a relevant marker of this resistance in Asia. Hence, it is worth considering that global 
sequencing effort for K13 is conducted to trace the distribution of ART resistance and to initiate 
the impact mitigation for supporting world malaria elimination program, especially in highest 
incidence level area in Africa. Furthermore, K13 mutations monitoring is included in the WHO 
criteria to follow ART resistance worldwide.  
 
 
97 
 
 
 
b. Corresponding publication       
98 
 
 
 
 
99 
 
 
 
 
100 
 
 
 
 
101 
 
 
 
D. Dihydroartemisinin-Piperaquine Resistance in Kupang 
Regarding the emergence of ART resistance and its spread in Asia, it is important to 
evaluate the level of ACTs resistance in Indonesia. Monitoring of K13 mutations is part of the 
WHO criteria to investigate ART resistance worldwide. Consequently, this gene is important 
to be examined during malaria clinical trials in Kupang to evaluate the possible ART resistance 
emergence in Indonesia. 
Even though there was no report of any treatment failure yet after ACTs treatment and 
linked to ART resistance in Indonesia, this study was undertaken on isolates coming from areas 
where P. falciparum has been recorded as strongly present to assess whether ACTs resistance 
can be detected through ex-vivo RSA assay.  
Ethics approval submission was the first step of the research parallel to a study of the 
population to define the most appropriate area among the endemic areas of malaria in 
Indonesia. Patients were eligible if they were aged 2-65 years, diagnosed for non-complicated 
malaria caused by particularly P. falciparum (slide-confirmed malaria), having fever (a 
tympanic temperature ≥ 37.5ºC) or history of fever 48 h preceding presentation and parasite 
density no more than 200,000 parasites per µL with minimum 0.5% parasitemia, seeking 
treatment in primary health center or regency referral hospital, and agreeing to sign the 
informed consent and follow the study. Patients were excluded if they were pregnant or 
lactating women, children under 5 kg, already taking malaria treatment for 4 weeks in advance, 
diagnosed for complicated malaria (co-infection), infected by other Plasmodium species than 
P. falciparum, and having signs of severe malaria, severe malnutrition, serious underlying 
disease (renal, cardiac, or hepatic), or known allergy to the study drugs. 
Dihydroartemisinin-Piperaquine (Darplex®) was administered during the first 3 days of 
the study and a follow-up was conducted until day 42. To perform ex-vivo RSA and K13 gene 
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identification, parasites were isolated from 3 mL of patient’s venous blood placed in ACD 
coagulant tube just prior to taking the drug. A couple drops of blood were examined for its 
parasitemia (thin smear), ± 100 µL was dropped into filter paper (Whatman® paper, Human 
ID Bloodstain card) for DNA extraction, and the remaining was prepared for RSA ex-vivo. 
 
 
Figure 13. Position of Kupang (circled) in the map of Indonesia [208]. 
 
After several evaluations based on the number of patients, laboratory facilities, and 
other factors, the most relevant area to conduct the research was Kupang Regency, East Nusa 
Tenggara, one of the areas with high malaria incidence in Indonesia. Furthermore, according 
to the Department of Health of Kupang (internal epidemiology data, 2015), there were 64,953 
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malaria cases in East Nusa Tenggara province and 831 positive cases of P. falciparum malaria 
found in Kupang Regency during 2014, and it was noted that there were 50 P. falciparum 
malaria patients seeking treatment in primary health-care center of Kupang Regency from 
January to June 2015 (based on a direct observation at the primary health-care center of Kupang 
Regency). The distance between Kupang Regency and the laboratory of BPOM Kupang as the 
laboratory center for conducting RSA assay also contributed to the choice of this population 
area. Since the patients’ blood withdrawal had limited time to be tested for its ACT resistance, 
the distance between the primary health-care center and laboratory became important. In the 
meantime, the ethics approval (ref. number: KE/FK/222/EC) from the Medical and Health 
Research Ethics Committee of the Faculty of Medicine, Gadjah Mada University, and research 
permits from each primary health-care center in Kupang Regency, referral hospital and BPOM 
Kupang were obtained prior to the beginning of the study. 
After one year of study, only 6 patients of P. falciparum malaria enrolled among whom 
one was developing severe malaria and one refused to continue the study after a week of follow-
up. As a result, only four patients met the criteria and were followed up for the study. The small 
number of P. falciparum malaria patients that had been found was contrary to the previous data 
collected from direct observation at the primary health-care centers of Kupang Regency (2015). 
It might be so because there was a decrease in the malaria prevalence in this area. Based on the 
report of the Department of Health, there were 36,128 malaria cases reported in this province 
during 2015 [209]. This number indicated a significant decline in malaria prevalence from 13 
API level in 2014 to 7 in 2015.  Additionally, the national annual parasite also reduced by 0.99 
to 0.85 in 2015 [4]. This finding was likely to represent the limited number of cases in 
Indonesia, particularly during our study in Kupang. Furthermore, this phenomenon occurs not 
only in Indonesia but also in other countries. A recent publication mentioned that malaria cases 
were declining by 54 % for last 3 years in Greater Mekong Sub-region (GMS) [210]. Several 
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factors that might influence the decrease number of malaria cases were climatic and non-
climatic. 
Climatic factors include temperature, rainfall, and relative humidity. The optimum 
temperature for parasite development is 27ºC. Temperature raise delays the parasite 
development in the gut of mosquito (more than 10 days). In addition, when the rain is delayed, 
the breed of mosquitos decreases. Moreover, lower relative humidity reduces the survival time 
of mosquito to transmit malaria. Based on the data from Metrological, Climatological, and 
Geophysical Agency (BMKG), the temperature in Kupang reached 31.07ºC with 65-90% 
humidity and 362 mm average rainfall. This condition was highly likely to affect malaria 
transmission. 
Non-climatic factors including urbanization and human host can have an impact on the 
transmission. The incidence of malaria is lower in urban area than in rural area, but the 
development in rural area may also influence malaria distribution. Moreover, there is a 
possibility that people already have immunity which makes better tolerance to the effects of 
malaria, and non-immune people believe that being infected by malaria is the same as common 
cold and does not need serious treatment in healthcare center. This makes many malaria cases 
under reported.  
In addition, malaria elimination program run by the government also takes part in case 
diminution. Specific strategies have been implemented by the government to expedite the 
elimination program. Since Kupang is one of the high malaria endemic areas, the acceleration 
strategies have been employed through mass ITNs campaign, early malaria detection and 
appropriate treatment [4]. The evidence of the number of malaria cases reduction may indicate 
that the elimination program runs well.  
105 
 
 
 
From the six eligible patients, bloods were taken and prepared for ex-vivo RSA. Thin 
blood smears were made to confirm the diagnosis and determine the parasitemia ratio. 
Unfortunately, all the blood samples which were delivered to the laboratory could not allow 
the detection of parasite presence although it has been previously held as positive P. falciparum 
malaria. We did not have access to the original smears in order to re-confirm whether the initial 
parasitemia met the eligible criteria (> 0.5%). Therefore, the ex-vivo RSA could not be carried 
out though the analysis of K13 mutation is currently in progress. Some possibilities are offered 
to assess the causes and provide the solutions. 
Theoretically, the blood must be processed right after having been taken since delayed 
processing can potentially undermine the parasite condition [211]. If the distance between the 
site of blood withdrawal and the laboratory to conduct the RSA assay is quite long, the blood 
should be transported in a cold temperature. It took approximately two hours from Kupang 
Regency to BPOM Kupang in Kupang city, therefore the patient’s blood was stored in an ice 
box during transportation. However, this did not work. A sudden temperature change from the 
patient’s body to the storage condition might contribute to this problem. Then, an approach 
was made by modifying the storage method. The blood was stored in a cold temperature (2-
10ºC) during the transport to the laboratory and placed in a room temperature during the 
preparation in laboratory. Yet, it did not work either. Moreover, since the authorized working 
hours in the laboratory were limited, the blood preparation was not possible to process on the 
same day. 
Another problem was related to the diagnosis process. The diagnosis was made by 
physicians based on patient’s blood smears prepared by technicians. Not all of the technicians 
were certified giving an impact on smear evaluation. There was a possibility that false positive 
diagnosis occurred. 
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These findings lead us to the following perspectives. Looking for another feasible study 
area which has a large number of P. falciparum cases, adequate laboratory facility and more 
flexible access to conduct the study outside working hours are strongly suggested. Furthermore, 
in order to perform RSA assay, it is important to understand the Indonesian parasite 
characteristic by modification of blood transport and storage conditions if a field laboratory is 
not available. Also, as K13 has a great impact on malaria control in Cambodia, it is interesting 
to work on K13 screening not only in one endemic district but also in several other endemic 
regions in Indonesia to get whole a map of K13 existence in Indonesia.  
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CONCLUSION AND PERSPECTIVES 
 
A. CONCLUSION 
 
Various efforts and studies have been undertaken to reduce malaria prevalence all around 
the world. This study points out several strategies for combating malaria particularly in 
antimalarial drug resistance. The approaches to solve antimalarial resistance problem include 
discovering new drugs, understanding the resistance mechanism, and investigating the 
occurrence of ART resistance in endemic area through identification of K13 gene mutation.  
The first approach is discovering new drug by assessing selected medicinal plants in 
Indonesia, namely T. diversifolia, C. barbata, T. crispa, A. flava and P. cauliflora. Those plants 
represent not only good antiplasmodial activity but also potential antibabesial and 
antileishmanial with P. cauliflora as the most promising medicinal plant for further 
investigation. 
Potential new drugs are also assessed by synthesizing organometallic compounds. Gold 
complex combined with NHCs is prospective as a new antimalarial synthetic drug since it 
exerts good antiplasmodial activity against CQ-resistant strain, especially in the cationic form, 
and has lipophilic properties.  
The second approach is done by understanding the role of K13-propeller mutation in 
artemisinin resistance. K13-propeller mutation mediates the occurrence of artemisinin 
resistance in vitro on both Cambodian clinical isolates and laboratory lines. 
The last approach is identification of K13-gene mutation in Kupang, one of the endemic 
regions in Indonesia. Unfortunately, it could not be established due to the limited number of 
samples. 
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B. PERSPECTIVES 
 
As Indonesia government intends to achieve malaria-free state by 2030, several 
schemes on antimalarial drug resistance should be dealt with in advance. Some of the schemes 
were explored in this study resulting in several outlooks as follows. 
First, selected plants from Indonesia have been proved to possess good antiplasmodial 
activity. Therefore, further phytochemical investigation is essential to explore the active 
compound of promising plants in order to discover new antimalarial drug. Additionally, a study 
on their mode of action will be more beneficial for the drug development.   
Another drug source, chemical synthesis from gold compound combined with NHC as 
a ligand, also presents a good activity against CQ-resistant parasite. Hence, immediate 
investigation on advanced pharmacology assays is required, including exploration of 
pharmacokinetics profile, stability study, and toxicity study before continuing to a clinical 
level. 
Third, exploring ART resistance mechanism has resulted in confirmation of K13-
propeller mutation role as a mediator in ART resistance. Indeed, global attempts for K13 gene 
sequencing are worth making to figure out the distribution in Southeast Asian countries, 
particularly in several endemic areas in Indonesia. Moreover, K13 mutation monitoring is 
included in the WHO criteria to follow ART resistance worldwide. 
Following the third perspective, the study on K13-propeller mutation in Kupang, one 
of the malaria endemic areas in Indonesia, has yet to be clearly conclusive. Follow-up attempts 
to investigate its occurrence are strongly suggested to look for another feasible study area 
which has a large number of P. falciparum cases, adequate laboratory facility and more flexible 
access to conduct the study outside working hours. Still, in order to perform RSA assay, it is 
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important to understand the Indonesian parasite characteristics by modification of blood 
transport and storage conditions if a field laboratory is not available. Also, as K13 has a great 
impact on malaria control in Cambodia, it is interesting to work on K13 screening not only in 
one endemic district but also in several other regions in Indonesia to obtain the whole map of 
K13 existence in Indonesia.
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